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Abstract 
 (Trans)dermal drug therapy is gaining increasing importance in the present-day drug 
development. To completely use the potential of skin administration, it is important to optimize 
the delivery of active ingredients/ drugs into/through the skin. The optimization of skin 
formulations could enhance the desired effect of the therapy and is often included in the early 
stages of the product development. Currently, most of the optimization is based on the use of 
appropriate ex vivo animal/human models. Alternatives to animals and human skin are impelled 
by economic and ethical reasons. In this context, the main goals of this study are to develop and 
characterize a stratum corneum model that mimics this human skin layer, inspired on a 
phospholipid vesicle-based permeation assay.  
 To mimic the stratum corneum layer, the phospholipid vesicles were prepared with a 
selected lipid composition, which closely corresponds to the main human lipid classes on this 
skin layer. The design of the developed model was optimized using dynamic light scattering, 
phospholipid quantification and scanning electron microscopy images. To compare the stratum 
corneum model developed, with the porcine skin model, the storage stability was assessed as 
well the calcein permeation in the presence of several conditions: a pH range, co-solvents and 
drugs. The established stratum corneum model could be stored at -20°C for up to 2 weeks 
without significant changes, was stable within the pH range from 2.0 to 8.0 and with the addition 
of co-solvents (DMSO, cremophor® and oleic acid). Additionally, the model showed a good 
correlation with the porcine skin model and provided reproducible results regarding the 
evaluation of the calcein permeability in the presence of some drugs (caffeine, naproxen, 
diclofenac, methotrexate, cyclosporine). 
In sum, the developed stratum corneum model allows permeation prognosis when 
examining drug formulations and can be stably stored. This model can thereby constitute a 
valuable tool to improve the process of (trans)dermal drugs development, as it may reduce the 
duration and the economic costs associated, and even replace the animal testing during early 
stages of drug development. 
Keywords: human stratum corneum, liposomes, permeability, transdermal drug delivery  
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Resumo 
            Atualmente, a administração de tratamentos por via transdérmica tem uma importância 
crescente no desenvolvimento dos medicamentos. No entanto, de modo a utilizar o potencial 
da administração através da pele, é importante otimizar a entrega de agentes ativos/ fármacos 
dentro e/ou através da mesma. A otimização de formulações pretende aumentar o efeito 
terapêutico pretendido quando aplicado na pele e, é um aspeto avaliado na fase inicial do 
desenvolvimento do produto. A maior parte da otimização é baseada no uso de modelos 
animais/ humanos, mas as questões éticas e económicas incentivam a procura de modelos 
alternativos. Neste contexto, este trabalho de investigação pretendeu desenvolver e 
caracterizar um modelo de estrato córneo que mimetize esta camada da pele humana, 
inspirada num ensaio de permeação baseado em vesículas fosfolipídicas. 
 De modo a mimetizar a camada do estrato córneo, foram preparadas vesículas de 
fosfolípidos com uma composição lipídica específica baseada nos componentes lipídicos desta 
camada de pele no Homem. O modelo desenvolvido foi otimizado usando técnicas de 
dispersão de luz, quantificação de fosfolípidos e microscopia eletrónica de varrimento. Para 
comparar o modelo de estrato córneo desenvolvido, com o convencional modelo de pele de 
porco, foram avaliadas: a estabilidade no armazenamento, a taxa de permeabilidade da 
calceína sozinha e na presença de várias condições (pH 2 a 8, co-solventes e fármacos). 
Conclui-se que o modelo de estrato córneo desenvolvido pode ser armazenado a -20 °C até 2 
semanas sem mudanças significativas relativamente ao seu perfil inicial de permeação, é 
estável no intervalo de pH de 2,0 a 8,0 e na presença de co-solventes (DMSO, cremophore® e 
ácido oleico). Além disso, o modelo mostrou uma boa correlação com o modelo de pele de 
porco e forneceu resultados reprodutíveis quanto à avaliação da permeabilidade da calceína na 
presença de alguns compostos com potencial terapêutico (cafeína, naproxeno, diclofenac, 
metotrexato e ciclosporina). 
 Em resumo, o modelo de estrato córneo desenvolvido permite o prognóstico da 
permeação de formulações de fármacos e pode ser armazenado de uma forma estável. Assim, 
este modelo pode constituir uma ferramenta valiosa para melhorar o processo de 
desenvolvimento de fármacos para via transdérmica e assim reduzir a duração e os custos 
associados dos tratamentos, e até mesmo substituir os testes em animais durante as primeiras 
fases de desenvolvimento de fármacos. 
 
  
iv 
 
Acknowledgements 
 Firstly, I would like to express my sincere gratitude to my research supervisor Dr. Sofia 
Lima, for the continuous support of my study and related research, for her patience, motivation, 
caring, new ideas and immense knowledge. Her guidance helped me in all the time of research 
and writing of this thesis. I could not have imagined having a better advisor and mentor for this 
work. 
 I would also like to show gratitude to Professor Salette Reis, for memorable opportunity 
to work in her research group, for positive atmosphere, sincere valuable guidance and 
encouragement extended to me. 
 I would also like to thank Dr. Cláudia Pinho for her teaching and assistance during lab 
work, the important suggestions and advices. I have always carried positive memories of her 
work with me. 
 I take this opportunity to express gratitude to all my professors in this Master’s degree 
for their help and training.  
 I would like to thank all members of Laboratório de Química Aplicada, especially to my 
colleges at Molecular Biophysics and Biotechnology, for their feedback, cooperation and of 
course friendship. It was fantastic to have the opportunity to work and great sharing laboratory 
with all of you during this year. 
 I also thank my family and friends for the support and attention, in particular to my aunt 
Jekaterina for her financial support and taking care. Finally, I must express my very profound 
gratitude to Aleksey for providing me with unfailing support and for always believing in me 
throughout my years of study and through the process of researching and writing this thesis. 
 This accomplishment would not have been possible without all of you. Thank you so 
much. 
  
v 
 
Contents 
Abstract ........................................................................................................................................................ ii 
Resume ....................................................................................................................................................... iii 
Acknowledgements ................................................................................................................................... iv 
Contents ...................................................................................................................................................... v 
List of Figures .......................................................................................................................................... viii 
List of tables ............................................................................................................................................... xi 
List of abbreviations ................................................................................................................................. xii 
I INTRODUCTION ...................................................................................................................................... 1 
1 Human skin ......................................................................................................................................... 1 
1.1 Structure of the skin ........................................................................................................................ 1 
1.1.1 Stratum Corneum: structure ................................................................................................... 2 
1.1.2 Stratum Corneum: lipid composition ..................................................................................... 4 
1.1.3 Stratum corneum: functions .................................................................................................... 6 
1.1.4 Viable Epidermis ....................................................................................................................... 8 
1.1.5 Dermis ........................................................................................................................................ 9 
1.1.6 Hypodermis ............................................................................................................................... 9 
2 Skin penetration ...................................................................................................................................... 9 
2.1 Routes of drug penetration through the skin ............................................................................. 10 
2.1.1 Intercellular pathway ........................................................................................................ 11 
2.1.2 Transcellular pathway ...................................................................................................... 11 
2.1.3 Appendageal pathway ..................................................................................................... 12 
3 Transdermal drug delivery .............................................................................................................. 12 
3.1 Skin models .................................................................................................................................... 13 
3.1.1 Ex vivo models ........................................................................................................................ 14 
3.1.2 In vitro models ......................................................................................................................... 15 
3.2 PVPA model ................................................................................................................................... 17 
4 Aims and Strategy ................................................................................................................................. 19 
II MATERIALS AND METHODS ............................................................................................................ 19 
1 Materials ................................................................................................................................................. 19 
2 Methods .................................................................................................................................................. 20 
2.1 Choice lipid composition for liposomes ...................................................................................... 20 
2.2 Preparation of liposomes .............................................................................................................. 21 
vi 
 
2.2.1 Preparation of the thin film .................................................................................................... 21 
2.2.2 Hydration of the thin film........................................................................................................ 22 
2.2.3 Sonication ................................................................................................................................ 23 
2.3 Particle size and polydispersity index ......................................................................................... 24 
2.4 Preparation of the human SC model .......................................................................................... 25 
2.5 Test compounds ............................................................................................................................ 26 
2.5.1 Calcein ..................................................................................................................................... 26 
2.5.2 Drugs ........................................................................................................................................ 27 
2.6 Permeation studies for human SC model .................................................................................. 29 
2.7 Permeation studies with Franz Diffusion Cells .......................................................................... 31 
2.7.1 Pig skin preparation ............................................................................................................... 31 
2.7.2 In vitro permeation studies .................................................................................................... 31 
2.7.3 Permeability calculations ....................................................................................................... 32 
2.8 Scanning Electron Microscopy .................................................................................................... 33 
2.9 Phospholipid quantification assays ............................................................................................. 33 
2.10 Statistical Analysis ....................................................................................................................... 34 
III RESULTS AND DISCUSSION .......................................................................................................... 35 
3.1 The structure of the phospholipid vesicle-based SC model ........................................................ 35 
3.1.1 Determination of size and polydispersity of the liposomes .............................................. 35 
3.1.2 Scanning electron microscopy analysis .............................................................................. 37 
3.2 Characterization of the phospholipid vesicle-based model ..................................................... 39 
3.2.1 Calcein permeability and electrical resistance ................................................................... 39 
3.2.2 Phospholipid quantification ................................................................................................... 40 
3.2.3. Storage stability ..................................................................................................................... 40 
3.2.4 Barrier stability under a pH range 2.0 to 8.0 ...................................................................... 42 
3.3 Characterization of drug–membrane interactions .................................................................... 43 
3.3.1 Use of pH changes to influence the permeability of acidic and basic drugs ................. 43 
3.3.2 Influence of surfactants and co-solvents in the phospholipid vesicle-based model .... 44 
3.3.3 Influence of drug substances on the SC model ................................................................. 46 
4 Comparison the SC model with pork skin model ............................................................................. 47 
4.1 Effect of storage conditions .......................................................................................................... 48 
4.2 Effect of various pH values (2.0 – 8.0) ....................................................................................... 49 
4.3 The influence of co-solvents and surfactant .............................................................................. 50 
vii 
 
4.4 Effect of acidic and basic drugs ................................................................................................... 51 
4.5 The influence of drug substances ............................................................................................... 52 
IV CONCLUSIONS AND FUTURE PERSPECTIVES ........................................................................ 54 
References and citations ......................................................................................................................... 55 
 
  
viii 
 
 
List of Figures 
Fig. 1 –  A diagrammatic view of the structure of human skin without hair in cross 
section 1 and histologic image of the human epidermis. The extracellular pH of the 
epidermis remains neutral until the transition between the stratum granulosum and 
stratum corneum, where it becomes more acidic towards the surface of the 
skin 2…………………………………………………………………………………………….. 2 
Fig. 2 – Two-compartment “bricks and mortar” system 3………………………………….. 3 
Fig. 3 – a. Stratum corneum structure: cornified envelope (blue); corneocyte lipid 
envelope (CLE, black); corneodesmosome (brown). b. Lamellar membrane structure 
with intercellular lipids. Insert, electron micrograph: Murine skin was fixed in 
Karnovsky’s fixative, and post-fixed with 1 % aqueous osmium tetroxide, containing 
1.5 % potassium ferrocyanide. Adapted from Uchida 4…………………………………….. 4 
Fig. 4 – Chemical structures of two SC ceramides and their possible conformations 5… 5 
Fig. 5 – Pathways into the skin for transdermal drug delivery. A. Intercellular pathway 
(penetration between the corneocytes through the intercellular lipids). B. Intrafollicular 
pathway (penetration through the hair follicles). C. Transcellular pathway (penetration 
through the corneocytes). D. Polar pathway (penetration through the polar pores) 
Adapted from Prausnitz 3……………………………………………………………………… 11 
Fig. 6 – A schematic representation of the estimated layout of PVPA 6…………………. 18 
Fig. 7 – The comparison between an original lipid composition of SC (inside circle) and 
the composition, which is used in this study (outside part) ……………………………….. 21 
Fig. 8 – Thin-lipid film formation ……………………………………………………………… 22 
Fig. 9 – Liposome suspensions: LUVs (right) and MLVs (left).……………………………. 23 
Fig. 10 – Schematic representation of liposomes preparation…………………………….. 24 
Fig. 11 – Flow chart for the preparation of the vesicular phospholipid barriers…………. 25 
Fig. 12 – The chemical formulas and structures of the studied drugs……………………. 28 
Fig. 13 – The experimental set-up used in the calcein permeation studies……………… 30 
Fig. 14 – Permeation studies with Franz Diffusion Cells…………………………………… 31 
Fig. 15 – Phospholipid quantification assays setup………………………………………… 33 
Fig. 16 – Size distribution of vesicles used in this study measured by DLS. (A) MLVs; 
(B) LUVs………………………………………………………………………………………… 36 
Fig. 17 – SEM images of (A-C) freshly prepared, and stored for 4 months at 4°C (D)  
ix 
 
the phospholipid vesicular barriers. The scale bar is indicated below images………….. 38 
Fig. 18 – SEM images of untreated human skin 7………………………………………...... 38 
Fig. 19 – The permeability of calcein for the pure filter inserts (control) and freshly 
prepared phospholipid vesicular barriers. The electrical resistance was marked by 
dots. The values denote the mean ± S.D. (n = 3)………………………………………….. 39 
Fig. 20 – Effect of storage conditions: -20°C and -80°C on calcein permeability and 
electrical resistance through the phospholipid vesicular barriers. Error bars represent 
the standard deviations (n=2 and for freshly prepared n=4). **P<0.01 in relation to 
freshly prepared membrane (control)……………………….……………………………….. 41 
Fig. 21 – The Papp and TEER values of calcein at pH 2.0, 7.4 and 8.0. Data expressed 
as mean values ± SD (n=5)…………………………………………………………………… 42 
Fig. 22 – The permeability (Papp) values for caffeine and methotrexate (MTX) at pH 
2.0, 7.4 and 8.0 in the apical medium and pH 7.4 the basolateral medium. 
****P<0.0001 between MTX pH2 and MXT pH8…………………………………………… 43 
Fig. 23 – The permeability (Papp) values for calcein in absence (control) and presence 
of different co-solvents and surfactant in the donor compartment. Error bars denote 
the standard deviations (n=3)………………………………………………………………… 45 
Fig. 24 – The permeability (Papp) values for calcein and the electrical resistance across 
the SC model in absence (control) and presence of caffeine, naproxen, diclofenac, 
MTX and cyclosporine. Each result represents the mean ± standard deviation for n=3 
measurements. ****P<0.0001 in relation to calcein alone ……........................................ 46 
Fig. 25 – Correlation between the calcein permeability (Papp) values from SC models 
and the obtained values from pork skin assay in terms of storage stability. Error bars 
represent standard deviations………………………………………………………………… 48 
Fig. 26 – Correlation between the calcein permeability (Papp) values from SC models 
(triangular dots) and from pig ear skin model (bars) towards pH range from 2.0 to 8.0. 
*P<0.05 in relation to calcein permeability at pH 7.4 for pig ear skin model…………….. 
 
49 
Fig. 27 – The calcein permeability (Papp) values from SC models (triangular dots) in 
comparison with Papp for pork skin from Franz diffusion cell assays (columns) in 
presence of the co-solvents. **P<0.01 in relation to control (calcein alone) ……………. 50 
Fig. 28 – Correlation between the calcein permeability (Papp) from pig ear skin 
experiments (left side) and from SC models (right side) in the presence of the acidic 
(MTX) and basic (caffeine) compounds toward the pH range from 2.0 to 8.0. *P<0.05 
in relation to caffeine pH 8 for pig skin model and ****P<0.0001 between MTX pH2 
 
 
 
 
x 
 
and MXT pH8 for SC model……………………………………........................................... 51 
Fig. 29 – The permeability (Papp) values for calcein for Franz diffusion cells studies 
(bars) and the SC model (dots) in absence (control) and presence of caffeine, 
naproxen, diclofenac, MTX and cyclosporine. Each result represents the mean ± 
standard deviation for n=3 measurements. *P<0.05, ** P<0.01, **** P<0.0001 in 
relation to calcein (alone) for pork skin………………………………………………………. 52 
  
xi 
 
List of tables 
Table 1 – Barrier roles of SC in maintaining epidermal homeostasis. Adapted from Uchida 4... 7 
Table 2 – Physical, chemical, and biological factors modulating the rate of penetration. 
Adapted from Pouillot 8………………………………………………………………………………… 10 
Table 3 – Transdermal drug delivery: theoretical benefits and limitations. Adapted from 
Prausnitz and Uchechi 3, 9…………………………………………………………………………….. 13 
Table 4 – Characteristic of different skin models used for optimization of topical formulation. 
Copyright © 2015 Elsevier B.V. All rights reserved 10……………………………………………… 16 
Table 5 – Liposomes composition……………………………………………………………………. 22 
Table 6 – Cycles of heating/vortex for liposomes preparation……………………………………. 23 
Table 7 – Specifications of the culture plate inserts.……………………………………………….. 26 
Table 8 – The physicochemical properties of drugs.………………………………………………. 27 
Table 9 – Characterization of the liposomes populations.………………………………………… 34 
 
  
xii 
 
List of abbreviations 
5-HT – 5-Hydroxytryptamine  
CAMP – Cathelicidin Antimicrobial Peptide 
CE – Cornified Envelope 
CLE – Corneocyte Lipid Envelope 
DLS – Dynamic Light Scattering  
DMSO – Dimethylsulphoxide 
EPC – Egg L-α-Phosphatidylcholine 
FFAs – Free Fatty Acids 
GLC – Gas/Liquid chromatography 
HEPES – 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid hemisodium salt 
LUVs – Large Unilamellar Vesicles 
MLVs – Multilamellar Large Vesicles 
MTX – Methotrexate 
Mw – Molecular weight  
NHKs – Normal Human Keratinocytes  
NMFs – Natural Moisturizing Factors  
NMR – Nuclear Magnetic Resonance 
NSAIDs – Non-Steroidal Anti-Inflammatory Drugs  
OECD – Organization for Economic Co-operation and Development 
PAMPA – Parallel Artificial Membrane Permeability Assay 
PBS –Phosphate Buffered Saline 
PDI – Polydispersity Index  
PDMS – Poly(dimethylsiloxane) 
xiii 
 
PSA – Polar Surface Area  
PVPA – Phospholipid Vesicle-based Permeation Assay 
S1P – Sphingosine-1-Phosphate  
SC – Stratum Corneum 
SEM – Scanning Electron Microscopy  
SUVs – Small Lamellar Vesicles 
TDD – Transdermal Drug Delivery  
TEER – Transepithelial Resistance 
UV – Ultraviolet  
VDR – Vitamin D Receptor 
 
 
 
 
1 
 
I INTRODUCTION 
1 Human skin 
The skin is the largest organ of the integumentary system, covering about 1.5 – 2 m2 of the 
human body surface area and on average calculating for 10% of the body mass for adults.5, 11 It 
determines the border between the human body and the external environment, which enables 
the biological vital functions. Nevertheless, the skin is more than just a physical barrier; it gives 
an important interface for interaction with the world. Thus, one of its most important roles is to 
regulate what enters and exits the body. Mainly, the skin is meant for very little penetration, 
while other tissues, for example the permeable epithelia of the lung and gastrointestinal tract 
provide the principal sources of regulated entry into the body. Additionally, the skin prevents the 
body´s dehydration, protects the body against pathogens, enables ultraviolet protection, 
thermoregulation, sensation, synthesis of vitamin D, and the protection of vitamin B folates. 
Finally, the skin has highly selective properties and different rate for intake.3 
The thin outer layer of the epidermis is the stratum corneum (SC). Generally, it is 
responsible for the barrier properties of the skin.12 SC is composed of corneocytes (mainly 
constituted by aggregated keratin filaments covered by a cornified envelope) that are enclosed 
by extracellular lipids, arranged as multiple lamellar bilayers.3 These lipid structures prevent 
excessive loss of water from the organism and block the entry of most topically administered 
drugs that have high molecular weight and low lipophilicity. Thereby, this barrier represents a 
great challenge for drug delivery across the skin, intended either for local effects or for systemic 
therapy. 
 
1.1 Structure of the skin 
Skin is a heterogeneous membrane, with hydrophilic properties in an internal layer and 
lipophilic on its outside area. Each tissue layer is composed of different cell types that have 
various functions. 
There are three structural layers of the skin: the epidermis, the dermis and hypodermis (or 
subcutis). Moreover, the epidermis can be subdivided into the stratum corneum (horny layer), 
stratum granulosum (granular layer), stratum spinosum (prickle cell layer) and stratum basale 
(Fig. 1). A complementary layer, the stratum lucidum (clear layer) can be found on the palm and 
sole of the foot, which is responsible for the thickened skin. Nevertheless, the stratum lucidum is 
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often considered the lower part of the SC but not an individual epidermal layer. There are also 
the hair follicles and sweat ducts that cross different skin layers.5 
 
Fig. 1 – Schematic representation of the structure of human skin without hair in cross section and histologic image of the 
human epidermis (https://commons.wikimedia.org/wiki/File:Epidermal_layers.png#/media/File:Epidermal_layers.png 
Downloaded July 25, 2017).
1
 The extracellular pH of the epidermis remains neutral until the transition between the stratum 
granulosum and stratum corneum, where it becomes more acidic towards the surface of the skin 
2 
 
1.1.1 Stratum Corneum: structure 
The SC is a multifunctional outermost layer of the epidermis. The SC is typically 10–20 µm 
thick and composed of 10–15 layers of corneocytes, denucleated forms of keratinocytes, for 
normal human skin on the body (on the palm and sole about 200 layers) embedded in a lipid 
matrix.4, 5 Differences in the layers are a function of body site and reflect the thickness, content 
of protein (filaggrin)and corneodesmosomes and packing of keratin filaments.3 The lipid layers, 
compose the permanent pathway through the SC and are indicated as the main barrier for 
diffusion of substances through the skin.13 
Corneocytes are lifeless cells obtained from terminally differentiated keratinocytes, during 
the passage from granular layers to SC. This process is characterised by loss of nuclei and 
cytoplasmic organelles, flattening and elongation of the keratinocytes. Morphological dimension 
of the corneocytes are about 0.2 µm thick and 40–60 µm wide.5, 14 Their membrane is 0.015 to 
0.020 µm thick and includes involucrin and keratolinin (structural proteins).8   
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The organisation of the SC is usually compared with the "bricks and mortar" model (Fig. 2). 
The bricks are the corneocytes (filled with keratin filaments, dried out, non-living skin cells that 
are ready to shed). The extracellular matrix analogous to the mortar in a brick wall, which is 
composed of lipids (stacked lipid bilayers that surround the corneocytes) like the cement holding 
the bricks together.3, 4  
 
Fig. 2 – Two-compartment “bricks and mortar” system 
3  
 
The process of continuous shedding of corneocytes from the skin surface is called 
desquamation.5 It balances proliferating keratinocytes that form in the stratum basale. The cells 
migration through the epidermis to the surface takes approximately fourteen days.2 
The interior of the corneocytes is filled with keratin filaments embedded in a matrix consisted 
principally of filaggrin (filament aggregating histidine-rich protein) and its breakdown products. 
These amino acids together with certain ions, such as chloride, sodium, lactate and urate, form 
the natural moisturizing factors (NMFs).2 NMFs are endogenous humectants that keep the 
hydration of the SC on an adequate level. It is important for skin elasticity and permits regularly 
function for hydrolytic enzymes of desquamation.15 Reduced levels of filaggrin and properly the 
Natural Moisturizing Factors (NMFs) are caused by mutations of the filaggrin gene connected 
with atopic dermatitis, ichthyosis vulgaris, psoriatic skin, ichthyosis, and general xerosis (dry 
skin).4, 15 
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Fig. 3 – a. Stratum corneum structure: cornified envelope (blue); corneocyte lipid envelope (CLE, black); corneodesmosome 
(brown). b. Lamellar membrane structure with intercellular lipids. Insert, electron micrograph: Murine skin was fixed in 
Karnovsky’s fixative, and post-fixed with 1 % aqueous osmium tetroxide, containing 1.5 % potassium ferrocyanide. Adapted 
from Uchida 
4
 
 
Corneocytes are enclosed by a cornified envelope (CE) that is formed by structural proteins 
crosslinked by transglutaminases.3 CE has a stable stiff property to withstand mechanical 
barrier stress (Fig. 3a), and is surrounded by a layer of corneocyte lipid envelope (CLE).4 This 
CLE is a support to form lamellar membrane structures and controls exit of hydrophilic agents 
from corneocytes, but the roles of CLE in the SC remain unidentified.4 
The extracellular space in the SC is filled by lipid-enriched layers.4 The lipids form lamellar 
membranes that stretch out in a horizontal direction parallel to the corneocytes (Fig. 3b). In 
addition, corneodesmosomes are found in the lamellar membrane structure. They are modified 
desmosomes including corneodesmosin, a structural protein that determines corneocyte 
adhesion.2 Corneodesmosomes consist of desmoglein-1 and desmocollin-1 connected to other 
corneocytes, intensify cohesion and regulate desquamation by their pH-dependent 
degradation.4 
 
1.1.2 Stratum Corneum: lipid composition 
Composition of SC is generally 20% of lipid and 70% of insoluble keratins.16 The majority of 
lipids is synthetized by keratinocytes in stratum granulosum and packed in lamellar bodies. 
a b 
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These organelles deliver their lipid content in the extracellular space by fusion with the plasma 
membrane of keratinocytes of the stratum granulosum.8 
The SC lipid composition research began as early as 1959, when 'the chemical composition 
of human epidermal lipids' was published.17 Development of methods such as gas/liquid 
chromatography (GLC) and nuclear magnetic resonance (NMR) studies improved the level of 
detail on this skin layer lipid composition.18 
Finally, the main components of the extracellular matrix are ceramides, cholesterol and free 
fatty acids, which are present in approximately equimolar ratios.3, 5, 19 Ceramides constitute 
approximately 50% of SC lipids mass 3, 5, 8 and have a critical role for the lamellar organization 
of this layer barrier.3 
The 14 ceramides classes, embracing 342 individual ceramide forms, have been recognized 
in the human SC.19 Of these, acylceramides or ceramides 1, 4 and 7 are epidermis-unique 
substances, which contain essential fatty acids in an ester linkage and important for barrier.3, 5 
Each ceramide molecule contains a polar head group from sphingoid component 
(sphingosine, phytosphingosine, 6-hydroxysphingosine or dihydrosphingosine) (dotted circle on 
Fig. 4) and two hydrocarbon chains derived from a fatty acid, a sphingoid or fatty acid ester 
moiety. 
Fig. 4 shows two molecular conformations of ceramides: the ‘hairpin’ or ‘tuning fork’ with the 
hydrocarbon chains pointing to the same direction and the extended or ‘splayed chain’ 
conformation, where the hydrocarbon chains adopt opposite directions.5 
 
Fig. 4 – Chemical structures of two SC ceramides and their possible conformations 
5
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The polar head groups can establish side hydrogen bonds and form lattice structures inside 
the lipid bilayers. In general, the hydrocarbon chains are saturated. The typical ceramide has a 
total of 38–54 carbon atoms.4, 5 
Cholesterol is the second most prevalent lipid by weight in the SC (25%).3, 8, 20 The 
increment of cholesterol concentration in the lipid bilayers correlates with the diminution of the 
membrane thickness and density, and at the same time with an extension of the membrane 
surface area. Cholesterol fluidizes the SC lipid bilayers at skin temperature.5, 20 
Content of free fatty acids (FFAs) is 10 – 15% of the SC lipids. FFAs consist mainly of very-
long-chain species with ≥18 carbon atom and are mostly saturated, like ceramides. 
In addition to lipid species, cholesterol sulfate is typically at 2–5 % weight ratio. Its potential 
functions are to help in the formation of the lipid lamellae and stabilization of the stratum 
corneum by inhibiting enzymatic degradation of corneodesmosomes.3, 5 
Any changes in the concentrations of these main lipid components can damage barrier 
integrity that mediates normal barrier function. 
 
1.1.3 Stratum corneum: functions 
Stratum corneum accomplishes barrier and immune functions. The most important 
properties of SC are presented in Table 1. 
The epidermal permeability barrier prevents intake and uptake of compounds. The SC 
barrier functions may be partially connected to its low hydration of 15%–20% and its very high 
density (1.4 g/cm3 in the dry state).16 The body temperatures maintenance and water balance 
are regulated by blocking surplus evaporation of water from nucleated layers. One of the basic 
properties of this barrier is the prevention of penetration of allergens, microbial pathogens and 
xenotoxic chemicals.4 As a general rule, a compound with molecular weight (Mw) larger than 
500 Dalton cannot pass through the SC.21 
The epidermis has a pH gradient: the extracellular pH stays neutral between the stratum 
granulosum and SC, where it becomes more acidic to ca. 4.5 at the outer SC layer (Fig. 1). 
Acidification enables antimicrobial activity and regulates, by enzymatic activity (proteases), the 
formation and desquamation of the epidermal barrier. The usage of alkaline or neutral soaps 
lead to the increase of the SC pH, which conducts to untimely cleavage of corneodesmosomes, 
decline in SC cohesion and following impairment of the epidermal barrier. The pH changes are 
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reported to matter in the pathogenesis of skin diseases such as atopic dermatitis, acne vulgaris 
and Candida albicans infections.2 For example, with pH below 5.5, the growth of Pseudomonas 
acne, Staphylococcus epidermidis, and a virulent microbial pathogen, Staphylococcus aureus, 
are inhibited.4 
 
Table 1 – Barrier roles of SC in maintaining epidermal homeostasis 
Barrier Roles Effectors 
Permeability 
Prevents excess water loss 
Primarily extracellular lamellar 
membrane structures 
Maintains body temperature 
Prevents ingress of xenotoxic chemicals 
and allergens 
Prevents invasion of microbes 
Antimicrobial 
Protects against diverse microbes 
(Gram-positive and Gram-negative 
bacteria, fungi, and viruses) 
Antimicrobial peptides 
Acidic pH 
Sphingoid bases 
Antioxidant Protects epidermis from oxidative stress  
α-/γ-tocopherol 
Ascorbic acid 
Glutathione 
Mechanical 
Protects epidermis from mechanical 
stress 
Primarily cornified envelopes 
UV 
Protects epidermis from cell death, DNA 
damage, and oxidative stress 
Urocanic acid 
Structural components (proteins, 
lipid, nucleotides) 
Adapted from Uchida.4 
 
The permanent bacterial flora in the skin presents a comprehensive ecosystem. 
Staphylococcus and Micrococcus strains and Diphtheroid bacilli are the main part of 
nonpathogenic microflora. They consume the sebum like basic nutrient, restrain skin coloni-
zation by potentially pathogenic organisms that protect the skin against pathogenic one.8 
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SC plays also an important role in the innate immunity, which is related with the presence of 
antimicrobial peptides such as cathelicidin, dermcidin, RNase7, S100A7/psoriasin and 
defensins. They show potent antimicrobial activities against a wide spectrum of microbes, 
including gram-negative and gram-positive bacteria, fungi, and some viruses. Cathelicidin 
antimicrobial peptide (CAMP) is inducible with infection, injury or inflammatory response and 
stimulates the production of a signal lipid, sphingosine-1-phosphate (S1P) under stress 
conditions and activate vitamin D receptor (VDR). The defensins are classified in three 
subfamilies, α-, β-, and θ-defensin. They are inducible peptides in epidermis in response to 
microbial infection, inflammation, and differentiation.4 
Adaptive immunity in the SC is associated with the availability of urocanic acid. The trans 
form of urocanic acid is generated from histidine (principally from NMF) by histidase, but can be 
converted to the cis form through exposure to ultraviolet (UV) radiation. Cis urocanic acid binds 
to the serotonin [5-hydroxytryptamine (5-HT)] receptor to eliminate immune function.22 Urocanic 
acid is an epidermal major chromophore, which works as a powerful endogenic UV absorbent. 
Most lower UV wavelengths (UVB = 280–315 nm) are absorbed in the epidermis, but longer 
wavelengths (UVA = 315–340 nm) get to the dermis. Also the bulk amounts of proteins, lipids, 
and nucleotides have individually low potent chromophores, but together can form the UV 
barrier.4 
The SC is constantly exposed to oxidants, including UV light, chemical oxidants and air 
pollutants. α- and γ-Tocopherol, ascorbic acid, and glutathione are the chief hydrophobic anti-
oxidants of SC, providing the lipid bilayers stability and safeguarding from lipid peroxidation.8 
 
1.1.4 Viable Epidermis  
The part of the epidermis that is formed by many layers of closely packed nucleated cells, 
with the exception of the SC, is called as the viable epidermis.5 The epidermis has an undulated 
geometry and connects with the dermis (Fig. 1) partially by fitting together projections 
(epidermal ridges or pegs) and recesses (dermal papillae).1 
The viable epidermis is generally 50–100 µm thick and contains no blood vessels and 
sensory nerve endings.3, 5 It is mainly constituted by keratinocytes (approximately 95% of cells), 
but three other types of cell are also found there: melanocytes, Langerhans cells and Merkel 
cells.5, 23 Keratinocytes originate from the stratum basale and expose oneself to progressive 
differentiation while migrating to the SC (described earlier, see Section 1.1.1) they are 
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necessary to maintain the SC by replacing lost corneocytes and SC lipids during 
desquamation.5 The steroid 7-dehydrocholesterol, present in keratinocytes, is transformed by 
sunlight to cholecalciferol. Activation of vitamin D takes place in the kidney.1 The viable 
epidermis is considerably hydrophilic (> 50%) in the opposite to SC.24 
 
1.1.5 Dermis  
The dermis is typically 1–2 mm thick and consists of collagenous (70%) and elastin fibers 
which give elasticity, flexibility and strength to the skin.3, 5 Hair follicles, sebaceous glands, 
sensory nerve endings, sweat glands, lymphatic vessels and blood capillaries found in the 
dermis and extend the dermal-epidermal junction. It allows to provide nutrients and oxygen 
delivery for both the dermis and epidermis.23 The dermis contains a range of immune cells 
including macrophages and dermal dendritic cells. It interplays with keratinocytes to provide 
stability of skin structure and heal over damage. The thermal barrier, energy depositary and 
protection from physical stroke is mainly connected with adipose tissue associated with collagen 
fibers, found in the lower reticular dermis layer. The water content in the dermis reaches 70%, 
promoting absorption of hydrophilic drugs. 
 
1.1.6 Hypodermis  
The subcutaneous layer or hypodermis is the innermost layer of the skin and consists of fat 
cells. However, this layer can be absent in some thin skin, for example on the eyelid. The 
hypodermis is between the skin and the subjacent tissues of the body, such as muscles and 
bone. Larger lymphatic and blood vessels are standing in this layer. Consequently, the major 
functions of the hypodermis are insulation, mechanical integrity and support and conductance of 
the vascular and neural signals of the skin.5, 23 
 
2 Skin penetration  
The skin is an attractive site for drug delivery and cosmetics. But normal skin is a serious 
barrier to drug absorption, which is why pharmacologists and cosmetologists became interested 
in the development of new drugs and ways of delivery (Table 2). Comprehension of the factors 
that influence the permeation via this barrier is necessary to obtain an effective transdermal 
therapy.3, 8 
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Table 2 – Physical, chemical, and biological factors modulating the rate of penetration 
    Physical and chemical factors Biological factors 
    Molecular mass 
    Concentration 
    Solubility 
    Partition coefficient 
    Variations of pH 
    Co-solvents 
    Temperature 
    Penetration enhancers 
Age 
Condition of the skin 
Metabolism of the skin 
Hydration of the skin 
Compound–skin interactions 
Adapted from Pouillot. 8 
 
Physical, chemical, and biological factors have an impact on the cutaneous absorption. 
They include molecular weight (preferentially lower than 500Da) 21, concentration, solubility, 
octanol/ water partition coefficient (very lipophilic molecules will distribute in SC but will transit 
with problems and hydrophilic molecules have bad intrusion), pH variations, co-solvents 
(increment the mobility of molecules), temperature (heat increases penetration), and penetration 
enhancers.8 
The biological parameters that influence the rate of skin penetration are age, skin type, level 
of the hydration, thickness of SC, amount and size of hair follicles or sweat ducts, condition, 
metabolism and sex hormones. Thus, skin location on the body has an important role in drug 
therapy.8 
 
2.1 Routes of drug penetration through the skin 
There are four possible routes of drug penetration across the intact skin (Fig. 5): 
intercellular, intrafollicular, transcellular and polar.8 Sometimes, the diffusion through the skin 
appendages (hair follicles and sweat glands) combine into the appendageal route.5, 25 Besides, 
the intercellular and transcellular ways are named the transepidermal pathway. The integrated 
flux of these all pathways defines the general observable flux through the skin.5 
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Fig. 5 – Pathways into the skin for transdermal drug delivery. A. Intercellular pathway (penetration between the corneocytes 
through the intercellular lipids). B. Intrafollicular pathway (penetration through the hair follicles). C. Transcellular pathway 
(penetration through the corneocytes). D. Polar pathway (penetration through the polar pores) Adapted from Prausnitz 
3
 
 
2.1.1 Intercellular pathway 
Transport through the intercellular area provides diffusion of lipophilic or non-polar 
compounds via the continuous lipid matrix.23 Furthermore, cationic molecules have a more 
effective adhesion with the negatively charged SC.8 In this pathway, the penetration goes by the 
tortuous path inside of the extracellular lipids and not cross the SC corneocytes. These lipids 
account for approximately 20% of the total volume of SC, but are the major way of penetration 
for most compounds. The matrix is separated in two parts:  a nonpermeable area (gel) and a 
permeable area (liquid-crystalline). The widest intervals between the intercellular lipids are 
0.013 µm. About 90% of the molecules penetrate the skin by this pathways due to lamellar 
organization of lipids.8 The lipid-enriched matrix of the SC not only limits transdermal delivery of 
hydrophilic drugs, but it works like SC “reservoir”  for the lipid-soluble drugs, which can amass 
and be slowly released, as for example topical corticosteroids.3 The majority of skin permeation 
enhancers, such as dimethylsulphoxide (DMSO), glycols and surfactants, can react with 
intercellular lipid bilayers by decreasing its diffusional resistance.3, 8 
 
2.1.2 Transcellular pathway 
The transcellular pathway via corneocytes, which abounds in keratin, allows the transport of 
hydrophilic or polar substances.23 It needs crossing the interlaced layers of cells and 
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extracellular matrix. Numerous stages of partition and diffusion are required to penetrate the 
drug through the cell matrix. The electrical (electroporation/ iontophoresis), mechanical 
(sonoporation/ sonophoresis) or thermal stimulus can give the gain of transdermal drug 
transport.9 
 
 
2.1.3 Appendageal pathway 
The skin appendages are hair follicles and sweat glands, which have a role in heat 
regulation and elimination of acids and body wastes. Its length is about 2-5 mm, from SC to 
dermis or hypodermis. Various sweat glands, oil glands, hair follicles and pores opening to the 
outer surface of the skin via their ducts, that can be used like possible way for entry. The nature 
of the pathway, arising in the sweat glands, is hydrophilic. These polar pores are located 
between cells and encircled by polar lipids, which make small holes in SC. The follicular orifices 
occupy only 1–2% of the total skin surface area and use for the intrafollicular way, sometimes in 
mixture with different surfactants and glycols.8 Hence, it was considered an inessential pathway 
for drug penetration. But current research found that hair follicles and sweat glands may offer an 
alternate pathway for a diffusing molecule.9 
 
 
3 Transdermal drug delivery  
Transdermal drug delivery (TDD) is a pain-free way of delivering drugs by applying a drug 
formulation onto the skin. The medicine firstly passes through the SC and then permeates via 
the viable epidermis and dermis by diffusion. After reaching the dermal layer, the drug becomes 
available for the uptake into the systemic circulation.23 
TDD has some advantages and disadvantages over other traditional routes of drug delivery 
(Table 3). The dermal and transdermal delivery systems have a lot of advantages in comparison 
with the oral route and hypodermic injections, but also have the limitations listed on Table 3. 
Nevertheless, TDD takes an important role in drug delivery and stays a demanding process 
notwithstanding the ability for potential skin absorption.9 
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Table 3 – Transdermal drug delivery: theoretical benefits and limitations 
Benefits Limitations 
 
 Painless self-administration for patients. 
 Improved efficacy, i.e. continuous 
release. 
 Reduced toxicity: no “peaks” and lower 
total absorbed dose. 
 In case of toxicity, the transdermal patch 
can easily be removed by the patient. 
 Avoidance of hepatic first-pass 
metabolism and the gastrointestinal tract 
for poorly bioavailable drugs. 
 Decreased dosing frequency 
 Decreased costs to patient due to 
decreased: total dose and dosing 
frequency (increased efficiency), as 
patches are designed to deliver drugs 
from 1 to 7 days. 
 Multiple dosing, on-demand or variable-
rate delivery of drugs is possible with the 
latest programmable systems. 
 
 Not all drugs are suitable for 
transdermal delivery. Drug 
requirements for TDD are high 
permeability, logPo/w=2-3, Mw < 500 
Da, dose less than 10 mg. 
 Drugs that require high blood levels 
cannot be administered. 
 The adhesive used may not adhere 
well to all types of skin. 
 Drugs or drug formulation may cause 
sensitization or irritation which must be 
evaluated early in the development 
process. 
 The patches may/can be uncom-
fortable to wear. 
 Specialized equipment for production, 
which results in more expensive 
medicines. 
 Not suitable for drugs requiring rapid 
onset of action (TDD has a lag time). 
Adapted from Prausnitz and Uchechi. 3, 9 
 
 
3.1 Skin models  
Validated data about permeation of compounds through human skin are needed for 
pharmaceutical, cosmetic and toxicological purposes. An efficient method for development and 
rationalization of drug formulation for the skin, demands specific skin models capable of 
estimating and determining topical properties of the formulation.  After the identification of 
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important penetration and permeation properties (wanted and unwanted) for the drug 
formulations, its optimization becomes achievable.10 
3.1.1 Ex vivo models 
During long time, the main way for the preclinical research of new drugs and for the 
optimization of topical drug formulations was the exploitation of ex vivo models. 
Human skin is absolutely the most suitable model for study TDD.26 Skin obtained from 
different origins: plastic surgery, amputation and cadaver, have been applied to ex vivo 
permeation assays. Generally, the skin samples can be collected from the abdomen, back, leg 
or breast.27 However, the use of human skin is very limited by the ethical permissions, 
regulatory issues and laboratory facilities. The European Union prohibits to get financial benefit 
from the utilization of human tissue, that is why widely-distributed usage is impossible.28 
Besides, the skin permeability is very changeable between the samples obtained from equal or 
different anatomical places of the same donor and has unpredictable character with different 
subjects or different age groups.10 
The ex vivo pig skin models are the most relevant animal models because of the multiple 
anatomical, physiological and histological resemblances to human skin such as the dermal/ 
epidermal thickness ratio, epidermal thickness, similarity in hair follicle and blood vessel density 
in the skin and content of SC ceramides, dermal collagen and elastin.29 The pig skin is easily 
obtained as a waste from animals slaughtered for food. The central outside part of the porcine 
ear has been recommended because of the analogy with human skin layers. Variability of 
permeability in different samples of pork skin also takes place. The pig ear skin permeability is 
comparable with human skin. In fact, studies showed a good correlation especially for lipophilic 
substances.10 
A wide spectrum of animal models involves the primates, mouse, rat, guinea pig, rabbit, 
bovine (udder) and snake (slough – shed skin) models. However, the primate research is highly 
restricted and very expensive. All these models besides bovine requires ethical permission in 
opposite to pig skin models. The dissimilarities in the thickness of SC, hair density, number of 
corneocyte layers, hydration, lipid profile and morphology are reasons of advantages and 
limitations and are listed on Table 4.10 
 Since 2009, the use of animals for collection of toxicological data for cosmetic ingredients 
has been prohibited in the EU (76/768/EEC, February 2003).28 That led to an expressed interest 
in in vitro models, which allow the penetration, permeation and skin irritancy assays.  
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3.1.2 In vitro models 
The using of skin equivalents started from normal human keratinocytes (NHKs) as a model 
for skin irritancy. There are several methods for growing keratinocytes. The culture of NHKs 
begins with a small piece of human skin (about 0.5-1 cm2) obtained from surgery after 
separation and specific treatment, that grows easily in culture medium. It allows the use of a 
large number of cells, leading to the opportunity for wide-ranging toxicity screening tests with 
many substances in a broad concentration range. This model has no SC layer, shows good 
ability for testing of water soluble compounds and less capability for evaluation of poorly soluble 
compounds and complex formulations.30 
The model has improved with its application in membranes, which support the NHKs during 
growing and forming the reconstructed human epidermis. The commercially obtainable models 
of the human epidermis (EpiSkin®, EpiDerm®, SkinEthic®) or full thickness skin (Phenion®) apply 
this approach in practice.28, 31 More improved models are the full-thickness skin consisting of the 
fibroblast populated collagen matrices (dermis equivalent) and an epidermal cover representing 
NHKs.28 They are well confirmed in a large German study.32 The results point to a higher 
permeation of the reconstructed skin models than of human epidermis and pig skin. 
Nevertheless, they are relevant alternatives for the in vitro rating of the permeation and 
penetration of substances when applied as aqueous solutions, especially in the early phases of 
drug formulation development.32 
To facilitate the determination of skin permeability, a few in vitro models have been 
presented, for example the silicone membranes or poly(dimethylsiloxane) (PDMS) 33, PAMPA 
(the ceramide-derived parallel artificial membrane permeability assay) 34 and the phospholipid 
vesicle-based permeation assay (PVPA).35 
The first PAMPA system included an artificial membrane from hydrophobic filter coated with 
phosphatidylcholine as a membrane barrier, which differentiates the donor and acceptor parts. 
That model was oriented for testing the transcellular intestinal permeability. Sinko at al. 
designed the skin-PAMPA, which consist of ceramides analogues called the synthetic 
ceramides, as substitution for native ceramides found in SC. The skin-PAMPA was used  in the 
skin permeability studies.34 The disadvantages are shown on Table 4. 
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Table 4 – Characteristic of different skin models used for optimization of topical formulation 
Skin model Advantages Limitations 
Silicone model 
membranes 
Reproducible 
Low cost 
Storage 
Non-lipid based 
Low resemblance to SC 
Non-biological origin 
PAMPA 
Reproducible 
Prolonged storage capabilities 
Low cost 
Synthetic lipids/non-lipid based 
Lipid organization not characterized 
Low resemblance to SC 
Non-biological origin 
PVPA 
Reproducible 
Lipid composition easily modified 
Relatively low cost 
Storage 
Lipid organization not characterized 
Non-biological origin 
Stratum 
corneum 
substitute 
Mimicking SC lipid organization 
Steady state flux similar to human SC 
Reproducible 
Lipid composition easily modified 
Relatively low cost 
Not used in formulation optimization yet 
Non-biological origin 
Reconstructed 
human skin 
equivalents 
Consistence in permeability in compari-
son to human skin 
More permeable than human skin 
Questionable barrier function 
High cost 
Pig ear 
Easily obtained (waste from slaughter) 
Similarity with human skin 
Age of animal influences skin thickness 
Removal of hairs (skin damage) 
Storage 
Newborn pig 
Thickness of the SC is similar to human 
horny layer 
Higher number of hairs than in humans 
Different anatomical sites: abdomen, back 
Difference in the skin thickness; newborn and 
older animals 
Storage 
Mouse 
Small size, uncomplicated handling 
Hairless species available 
 
Ethical permission 
Very thin skin, highly permeable 
High density of hair follicles 
Removal of hairs (skin damage) 
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Rat 
Small size, uncomplicated handling 
Hairless species available 
Ethical permission 
Thin skin, more permeable than human 
High density of hair follicles 
Removal of hairs (skin damage) 
Guinea pig 
Similar permeability to human and pig 
ear skin 
Hairless species available 
Ethical permission 
High density of hair follicles 
Removal of (skin damage) 
Rabbit 
Ears as waste from slaughter 
Similar permeability to guinea pig 
Ethical permission 
High density of hair follicles 
Removal of hairs (skin damage) 
Shed snake 
Single animal provides repeated sheds 
Multiple samples from one shed 
Storage at room temperature 
Absence of hair follicles 
Differences in skin metabolism, compared to 
human skin 
Absence of living epidermis and dermis 
Bovine udders 
Perfused 
bovine udder 
skin (BUS) 
Easily obtained (waste from slaughter) 
BUS-comparable to living skin 
Multiple samples from one animal 
One donor enables testing of only one 
sample (BUS) 
Weaker barrier to some drugs than pig skin 
Storage 
Human The most relevant model 
Ethical permission 
Higher inter- and intra-variability than with 
porcine ear skin 
Different sources: age, sex, race, plastic 
surgery, amputation, cadaver 
Different anatomical parts: abdomen, tight, 
breast, back, etc. 
Storage 
Copyright © 2015 Elsevier B.V. All rights reserved.10 
 
3.2 PVPA model 
Lately a new PVPA model, which imitates the SC barrier of the skin was developed.35  
Although the original PVPA was presented as model for screening the intestinal permeability 
and is composed of a consistent coat of liposomes deposited on a filter support acting as 
biological barrier (Fig. 6).6, 36 
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Fig. 6 – A schematic representation of the estimated layout of PVPA 
6
 
 
The arrangement shown in Fig. 6 is based on hypothesis and implies that the liposomes are 
located within the pores and on the surface of the membranes.6 The PVPA barrier has good 
abilities for a high-throughput permeability screening model 37 and is easily changeable in the 
composition of the liposomes making possible to mimic various absorption barriers. The PVPA 
can mimic different biological barriers just by the change of the lipid constituents in the 
models.35  In resume, skin PVPA models have been prepared with two different lipid 
compositions:  
- PVPAc consists of liposomes made of cholesterol (22.9%, w/w) and egg phospha-
tidylcholine EPC (77.1%, w/w).35 
- PVPAs from lipid mixture (EPC (50%, w/w), ceramide (27.5%, w/w), cholesterol (12.5%, 
w/w), free fatty acid (7.5%, w/w) and cholesteryl sulfate (2.5%, w/w).35 
The permeability of compounds was evaluated in these PVPA skin models. The results were 
compared with reported permeabilities using animal skin (rat, cattle, dog and pig) and estimated 
in silico values. The PVPA permeability data mainly corresponded with the literature values of 
the animal skin penetration assays and the calculated values with the exception of flufenamic 
acid that showed a relatively lower permeation.35 
In a following study, the PVPAs model was examined with different types of liposomes 
containing diclofenac sodium salt. The results showed a rising permeation ranking of diclofenac 
sodium from liposomal formulations correlating with the physicochemical parameters of the 
liposomal vehicle. The permeability of diclofenac increased in the availability of the penetration 
enhancers and edge activators within the liposomes.38 
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Recently, the developed PVPA skin models were compared with the reconstructed human 
skin model, EpiSkin®. The permeability result indicates that the PVPA has the ability to 
differentiate between the liposomal formulations and drug solutions as opposed to EpiSkin®. In 
short, the PVPA models were better than EpiSkin® concerning their potential to determinate the 
influence of the formulations on the drug permeability which could be used in drug development 
at early stage. Moreover, PVPA barriers had straightforward, effectiveness, economical and 
long storable.39 
 
4 Aims and Strategy 
The ability of skin models to predict permeation of trans(dermal) drug formulations has high 
significance for both drug therapy and cosmetic treatment.38 In the current time, prohibitions and 
limitations regarding animal skin usage lead to an increasing interest in the investigation and 
development of in vitro models. The PVPA model is one of them, and has showed good results 
and wide perspectives for the early design stages of drugs and cosmeceuticals.35, 39 
The aim of this study was to develop phospholipid vesicles models with adequate 
composition to reproduce the SC most accurately. Two objectives were identified for this study: 
1) to design and characterize phospholipid-based permeation assay membranes; 2) to compare 
permeabilities obtained with the SC model and in animal skin. 
 
II MATERIALS AND METHODS 
1 Materials 
Stearic acid was obtained from Merck KGaA, Darmstadt, Germany. Egg chicken ceramide, 
cholesterol (ovine wool) were purchased from Avanti Polar Lipids (Alabaster, Alabama). L-α-
Phosphatidylcholine (egg yolk), calcein, Dulbecco’s phosphate buffered saline (PBS), sodium 
cholesteryl sulfate, dimethyl sulfoxide, oleic acid, cremophor® EL (Kolliphor® EL), naproxen 
sodium, diclofenac sodium, cyclosporine, caffeine, sodium chloride, 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid hemisodium salt (HEPES), potassium 
phosphate monobasic, L-ascorbic acid and perchloric acid were supplied by Sigma-Aldrich (St 
Louis, MO, USA). Methotrexate was a gift from Excella (Feucht, Germany). Ammonium 
molybdate was obtained from AnalaR® (BDH Laboratory Supplies, Poole, England). 
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96-well, black plate, flat bottom with lid and 24-well plate flat bottom with lid were obtained 
from Falcon, Corning Incorporated, NY, USA. 96-well UV-Star® microplate, flat bottom (Chimney 
well), μClear® were supplied by Greiner Bio-one, Frickenhausen, Germany. Millicell culture plate 
inserts, polycarbonate (tissue culture-treated, Isopore track-etched PVP-free polycarbonate, 
pore size is 0.4 μm, d = 12 mm) were purchased from Millipore Corporation, Merck KGaA, 
Darmstadt, Germany). 
Double-deionized water was provided by an ultra-pure water system (Arium Pro, Sartorius 
AG, Gottingen, Germany). The reagents were weighted in a digital analytical balance Kern 
ACJ/ACS 80-4 (Kern & Sohn; Balingen, Germany). pH measurements were achieved using a 
Crison pH meter GLP 22 with a Crison 52-02 tip (Crison; Barcelona, Spain). 
Pig ear skin was purchased from a local commercial butcher (Porto, Portugal).  
 
2 Methods 
2.1 Choice lipid composition for liposomes 
To establish the conditions needed to the phospholipid vesicular model mimic only the 
human SC barrier 35, 38, a search of the SC lipid composition was conducted. The main 
components of the human SC lipid matrix, described in the literature, are ceramides (50% w/w), 
cholesterol (25% w/w), free fatty acids (10–15% w/w) and cholesterol sulfate (2–5 % w/w).3, 5, 8 
Thus, the following composition: ceramide (50% w/w), egg L-α-phosphatidylcholine (EPC, 25% 
w/w), cholesterol (12.5% w/w), free fatty acids (10% w/w) and cholesteryl sulfate (2.5% w/w) 
was selected to prepare the lipid-based vesicles. The relation between the commonly described 
as human SC lipid composition and the one selected for this work is showed in Fig. 7. 
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Fig. 7 – The comparison between an original lipid composition of SC (inside circle) and the composition, which is used in this 
study (outside part) 
 
The addition of EPC is to assure the formation and longer stability of the liposomes 40 and a 
reduction in the cost of the model. Differences between lipid composition in previous literature 
works 35, 39 and this study consist in the attempt to have a more closely human SC lipid 
composition (here, about 86% lipids correspond to the SC layer). 
 
2.2 Preparation of liposomes 
The liposomes were prepared through the thin-film hydration method followed by 
sonication.41 This method includes preparation of a thin lipid film in a round-bottom flask by the 
evaporation of organic solvents. Heterogeneous liposomes were formed by the addition and 
agitation of phosphate buffer (PBS), the multilamellar large liposomes (MLVs). Finally, after 
sonication large unilamellar liposomes (LUVs) were obtained. 
 
2.2.1 Preparation of the thin film 
Lipid mixtures were prepared according to Table 5 as a close approximation to the 
composition of human SC 42 but without the small proportions of cholesteryl esters and other 
minor constituents.  
 
 
 
[VALUE]% 
Cholesterol 
12.5% Other 
[VALUE]% 
Ceramide 
[VALUE]% FFA 
2.5% Cholesterol 
sulfate 
12.5% Cholesterol 
[VALUE]% EPC 
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Table 5 – Liposomes composition 
Component Mass (%) Mass (mg) 
Ceramide 50 10.0 
EPC 25 5.0 
Cholesterol 12.5 2.5 
FFA (Stearic acid) 10 2.0 
Cholesteryl Sulfate 2.5 0.5 
Total 100 20.0 
 
The lipid mixtures (20.0 mg) were dissolved in a 
mixture of chloroform and methanol (3:2 v/v) and were 
transferred into a 100-mL glass round-bottom flask. 
The solvents were evaporated in a rotary evaporator 
under a nitrogen stream (P=1.0 Bar) and a heating 
bath at 40°C for 30 min (Fig. 8). 
 
 
 
 
2.2.2 Hydration of the thin film 
5 mL of PBS were added in the dry lipid film and vortexed 10 min at room temperature. A 
final concentration of 4 mg/mL (20 mg in 5 mL PBS) was obtained. Then repeated cycles of 
heating and vortex were performed until the lipid film was detached (Table 6). At the end all the 
lipid material was suspended in solution, the flask was covered with a piece of stretched 
parafilm to prevent the entry of dusts or contaminants and were left at 4°C overnight to assure 
an efficient hydration of the lipid materials. The next day, two cycles of heating/vortex were 
reiterated again for formation of multilamellar vesicles (MLVs). 
 
 
 
 
 
 
Fig. 8 – Thin-lipid film formation 
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Table 6 – Cycles of heating/vortex for liposomes preparation 
Temperature Heating time Repeat 
50°C 5 min two times 
60°C 5 min two times 
65°C 3 min one-time 
  4°C           Store overnight 
65°C 5 min one-time 
70°C 5 min one-time 
 
2.2.3 Sonication 
 
The suspension of MLVs was divided into two 
portions to obtain liposomes of two different sizes. The 
ultrasonicator (Ultrasonic Processor for Small Volume 
Applications, Sonic Vibra-Cell) was used for LUVs 
production with amplitude 70% until the suspensions 
became clear (2 to 3 min) (see Fig. 9).25 A schematic 
representation for this method is shown on Fig. 10. 
 
 Fig. 9 – Liposome suspensions: LUVs 
(right) and MLVs (left) 
Fig. 10 – Schematic representation of liposomes preparation 
 
24 
 
2.3 Particle size and polydispersity index 
Dynamic light scattering (DLS) is a well-known method for the characterization of particles, 
molecules or emulsions, which have been dispersed in a liquid. In DLS, the laser light is 
dispersed with various intensities depending on the Brownian motion of particles or molecules in 
suspension. Analysis of these intensity variations determines the velocity of the Brownian 
motion and therefore the particle size using the Stokes-Einstein equation.43 
The mean size and polydispersity index (PDI) of the liposomes (LUVs and MLVs) were 
evaluated using a Particle Size Analyzer (Brookhaven Instruments Corporation; Software: 
Particle Sizing v.5 Brookhaven Instruments; Holtsville, NY, USA). The samples were diluted 20 
x with PBS buffer and then analyzed under the following parameters: run – 2 times, run duration 
– 1 min, temperature – 25.0°C, angle – 90.00º, wavelength – 660.0 nm. 
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2.4 Preparation of the human SC model 
The method involved the deposition of liposomes onto a filter support based of culture 
inserts, to obtain a barrier for transport studies. Phospholipid vesicle-based barriers were 
prepared as described previously, with few modifications.35, 36 Briefly, the preparation of the 
human SC model is outlined in Fig. 11. Sterile culture inserts (pore size 0.4 μm, d = 12 mm) 
were used (Table 7). Freshly prepared LUVs and MLVs were vortexed and kept at room 
temperature before addition. 
 
 
Fig. 11 – Flow chart for the preparation of the vesicular phospholipid barriers 
 
In resume: 
 An aliquot of liposomal suspension (100 μL of LUVs) was added to each culture inserts. 
The inserts were fixed into tubes, covered with a lid and centrifuged (Allegra X-15R, 
Beckman Coulter) at 950 g for 15 min at 20°C, to force the suspension pass through the 
filter. 
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 Then an additional amount of LUVs suspension (100 μL) was applied. The inserts were 
rotated 180° horizontally, followed by centrifugation under same conditions for 15 min. 
 Thereafter, inserts were in open tubes and heated at 45°C for 60 min (new step in 
relation to the described protocol:35 lower temperature and extended exposition of time 
because the inserts have temperature limit 50°C). This stage was made to enhance the 
viscosity of the suspension and to promote covering of the filter with liposomes. 
 After another portion of the liposome suspension which contains MLVs (bigger 
liposomes) was added in the amount of 100 μL to each insert and centrifuged at 1030 g 
for 60 min at 20°C. 
 Upon centrifugation, the excess of the supernatant was removed with a micropipette, the 
barriers were tilted at 45 degrees and the supernatant was accurately collected without 
touching the filter surface. 
 Then, the inserts were centrifuged in an inverted position (Fig. 11) at 20 g for 5 min at 
20°C. 
 Thereafter, inserts were transferred to fresh dry wells in a 24-well culture plate, covered 
with a lid, and then were frozen at -80°C overnight and thawed in open wells at 30°C for 
120 min in the next morning.  
 
Table 7 – Specifications of the culture plate inserts 
 
Height (including feet) 10 mm 
Height of feet 1-2 mm 
Outer Diameter 12 mm 
Inner Diameter 10 mm 
Membrane Area (effective) 0.6 cm2 
Temperature limit 50°C 
Membrane pore sizes 0.4 μm 
 
2.5 Test compounds 
2.5.1 Calcein 
Calcein (other name is fluorexon), is a widely known fluorescence dye.44 It is a hydrophilic 
and charged marker exploited in the capacity of being an efficient indicator to describe the 
properties of (model) biomembranes 45 and to evaluate the trans-bilayer permeability.46 
Moreover the calcein-release effect has been explored with respect to the design of novel drug-
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delivery systems 47 and calcein has been used like a model of hydrophilic and relatively low 
molecular weight (622.55 g/mol) drug.48 Calcein has been also used as a reference compound 
and an indicator of potential aqueous pathways in the lipid layer due to its chemical properties.49 
Thus, to confirm the model's ability to evaluate skin drug permeation a solution of calcein was 
applied.50 
The stock solution with 1 mM concentration was prepared by dissolving calcein in buffer 
pH 7.4 (PBS or HEPES for phospholipid quantification assay) on a sonication bath (Sonica® 
Ultrasonic Cleaner). It was stored at room temperature and protected from light sources. The 
different standard solutions (1.56 - 25 ·10-3 mM) were prepared and the fluorescence measured 
in a microplate reader (Synergy™ HT Multi-Detection Microplate Reader, BioTek®) with 
excitation and emission wavelengths at 485 nm and 528 nm, respectively, for the linear 
calibration curve. 
 
2.5.2 Drugs 
The drugs: caffeine, naproxen, diclofenac, methotrexate and cyclosporine were chosen to 
validate the SC model. They cover a wide range of physicochemical properties (molecular 
weight, pKa, log D and polar surface area, PSA), which are shown in the Table 8.  
Table 8 – Physicochemical properties of the drugs used in this work 
Drug Mw log Da PSAa pKa
b Fa (%)
a 
Caffeine 194.2   0.02 59.2 14 (25°C)*  100 
Naproxen sodium 252.24   0.23 56.2 4.15 98 
Diclofenac sodium 318.13   1.15 42.4 4.0 100 
Methotrexate 454.44 −2.53 225.9 4.7 47 
Cyclosporine 1202.64   2.31 - 9.45* 35 
a Log D (partition coefficient), PSA (polar surface area) and Fa (fraction absorbed in 
humans after oral administration) values were taken from Zhu.51 
b pKa (dissociation constant) values were obtained from Prankerd 
52 except those which 
marked with * which were taken from Swarbrick, Luo 53, 54 and Oliyai.55 
 
Caffeine is a stimulant of the central nervous system and may evoke sleepless and promote 
mental ability.56 The main benefits asserted for application of caffeine in cosmetics lies in 
averting redundant fat accumulation in the skin, lymphatic drainage promotion and skin 
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protection against the UV radiation. Scientific proof for many of these described advantages is 
missing and most of the literature studies are based on cell culture or mouse models.57 
Nevertheless, caffeine is recommended as a test substance by the OECD (Organization for 
Economic Co-operation and Development) because it has been extensively studied in vitro and 
in vivo.58 Also it is used as a model hydrophilic compound in dermal risk assessment studies 
and skin toxicology.54 
Naproxen and diclofenac are two non-steroidal anti-inflammatory drugs (NSAIDs) and they 
are generally prescribed for patients affected by dermatitis 59 and rheumatic diseases.60, 61 
Lately, development of various strategies such as penetration enhancers and the prodrug 
approach has been utilized to enhance the topical absorption of NSAIDs.62, 63 
The chemical formulas and structures of the studied drugs are presented in Fig. 12.  
 
Caffeine Naproxen sodium Diclofenac sodium 
C8H10N4O2 C14H13NaO3 C14H10Cl2NNaO2 
  
 
Methotrexate Cyclosporine 
C20H22N8O5 C62H111N11O12 
 
 
 
Fig. 12 – The chemical formulas and structures of the studied drugs 
Methotrexate is an antimetabolite drug, which has anti-inflammatory and 
immunosuppressant properties. It has shown effective abilities in treating diseases such as 
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tumors (e.g. skin and breast cancer, osteosarcoma), psoriasis and rheumatoid arthritis.64 
However, one of the methotrexate's limitations is the toxic side effects. Some studies have 
improved methotrexate formulations for topical treatment of skin diseases.65 
Cyclosporine (or cyclosporin A) has been clinically used for the treatment of inflammatory 
and autoimmune diseases, including skin disorders like psoriasis 66 and severe atopic 
eczema.67 Topical delivery of cyclosporine is a promising strategy to treat skin disorders, since it 
avoids several side effects associated with systemic delivery.66 
Stock solutions of the test compounds were prepared by dissolving the drug in phosphate 
buffer pH 7.4 (for methotrexate and cyclosporine with addition of 10% (v/v) DMSO and 20% 
(v/v) ethanol, respectively) on a sonication bath (Sonica® Ultrasonic Cleaner). The caffeine, 
naproxen, diclofenac, methotrexate and cyclosporine concentrations were 0.52, 0.012, 0.5, 0.5 
and 0.18 mg mL-1 respectively. 
These compounds were applied in the mixture with calcein solution and the changes of 
calcein permeation was evaluated by measuring its fluorescence in the presence of each 
studied drug with wide range of the physicochemical properties. For each studied drug a 20% 
(v/v) stock solution in 1 mM calcein solution was added in the donor chamber, with means that 
the studied concentrations were 104 μg mL-1 for caffeine, 2.4 μg mL-1 for naproxen, 100 μg mL-1 
for diclofenac, 100 μg mL-1 for methotrexate, 36 μg mL-1 for cyclosporine. All solutions were 
freshly blended before the calcein permeation studies. 
 
2.6 Permeation studies for human SC model 
Before the permeation experiments, the freshly prepared SC models were incubated with the 
buffer (PBS or HEPES for phospholipid quantification assay only) for 15 min.68 The inserts were 
placed in the individual acceptor compartments in 24-well plate containing 2 mL of PBS or 
HEPES (pH 7.4) for each cell and were fixed (Fig. 13). The contact with buffer promoted a 
better saturation of the liposome layers. Permeation studies were performed after adding 1mM 
calcein solutions (alone or with addition of described compounds) in the inserts. 
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Fig. 13 – The experimental set-up used in the calcein permeation studies 
 
The permeation experiments were carried out at room temperature without agitation (for all 
experiments besides phospholipid quantification assay) and with protection from light. The 
inserts were moved by tweezers to wells containing an equal quantity of fresh buffer (2 mL) at 
30 min intervals for 3 h of study. At the end of the experiment, samples (300 μL) from each 
acceptor compartment were transferred into 96-well black plates and analyzed at 20°C in a 
microplate reader with excitation and emission wavelengths at 485 nm and 528 nm, 
respectively.6, 36 
For the permeation studies with co-solvents, DMSO, oleic acid and cremophor® were used. 
The concentration of co-solvents was 10% (v/v) in calcein solutions. The mixtures were 
vortexed for 1 min and immediately loaded on the donor chamber.69 
The permeation assays were conducted under a pH range from 2.0 to 8.0 with 1 mM calcein 
solutions for pH 2.0, 7.4 and 8.0 (pH adjustment with HCl/ NaOH to the necessary value) in the 
donor cell and PBS (pH 7.4) in the acceptor chamber 6. The influence of pH changes in the 
permeability of acidic and basic drugs was determined by using 100 μg mL-1 methotrexate (pH 2 
and pH 8) and 104 μg mL-1 caffeine (pH 2 and pH 8) in the calcein solution. The acceptor 
compartment contained PBS pH 7.4.69 
The stability of the membranes during storage at two different temperatures (-20°C and -
80°C) up to two weeks was evaluated by performing permeation experiments using 1 mM 
calcein solution.6 
The transepithelial resistance (TEER) of the lipid barriers was measured (EVOM2®, 
Epithelial Volt/Ohm (TEER) Meter with STX2 electrodes, which contains a silver/silver-chloride 
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pellet for measuring voltage and a silver electrode for passing current, World Precision 
Instruments) directly after the end of permeation studies.38 
 
2.7 Permeation studies with Franz Diffusion Cells  
2.7.1 Pig skin preparation 
The young white porcine ears from different animals were initially cleaned and dried with 
soft paper, then the exterior skin was removed from the underlying cartilage using a knife. The 
subcutaneous fat tissue was cut off by a scalpel cautiously to keep the integrity of the pig skin. 
Porcine skin samples were gently dry-shaved if necessary, when not used immediately. The 
skin was packed in aluminum foil, marked and stored at 4°C up to 2 days or at -20°C up to 2 
weeks. These samples were kept at room temperature for 30 min before being used in the 
experiment.70 For each experiment, the skin was divided in pieces with same thickness 
generally from central part of the ear skin, visually inspected to ensure its integrity, no content 
blood vessels and skin defects. 
 
2.7.2 In vitro permeation studies 
The skin permeation of the control calcein-containing solutions described above were 
evaluated using a Franz cell assembly (9 mm unjacketed Franz Diffusion Cell with 5 mL 
receptor, O-ring joint, clear glass, clamp and stir-bar; PermeGear, Inc., USA). Pig ear skin was 
placed between donor and acceptor compartments in the Franz diffusion cell and held in place 
with a clamp (Fig. 14). 
 
Fig. 14 – Permeation studies with Franz Diffusion Cells 
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A volume of 0.5 mL of the test solutions with a known concentration were loaded in the 
donor chamber, the receiver chamber was filled with 5 mL of PBS (pH 7.4) and each cell was 
covered with Parafilm®. The diffusion area between cells was 0.64 cm2.70, 71 The Franz Cell 
system remained at room temperature upon 3 h of study. The acceptor compartment also 
contained a magnetic stir-bar, promoting stirring during 1 min prior sample collection. Aliquots of 
0.5 mL were collected at time 0.5, 1, 1.5, 2, 2.5, 3 h from the sampling port and replaced with 
the same amount of fresh buffer. 
All collected samples were analyzed by fluorescence measurement in the microplate reader 
with excitation and emission wavelengths at 485 nm and 528 nm, respectively. The 
quantification of the calcein concentration was obtained by the linear equation obtained from a 
prepared standard curve. 
 
2.7.3 Permeability calculations 
After fluorescence measurements, the concentration of calcein in the acceptor chamber was 
calculated using calibration curve. Mass of calcein in every lower compartment was accounted 
by next formula: 
𝑚𝑎(𝑔) = 𝐶𝑎 ∙ 𝑉𝑎 ∙ 𝑀𝑤      (1) 
 
where Ca is the calcein concentration in the acceptor chamber (M), Va is the volume of the 
lower chamber (2·10-3L) and Mw is the molar mass of calcein ( 622.55 g mol-1). 
For the permeation studies with Franz Diffusion Cells similar calculations were performed. 
Mass of calcein was computed for each sampling aliquot (0.5 mL), for last volume of acceptor 
cell (5 mL) and finally summarized. 
The obtained masses were then used to estimate the apparent permeability coefficient (Papp) 
by use following equation: 
𝑃𝑎𝑝𝑝(𝑐𝑚/𝑠) =
∑ 𝑚𝑎
𝐴·𝑚𝑑·𝑡
       (2) 
 
Where sum of ma is the mass of calcein permeated across membranes in acceptor 
chamber (g), A is the surface area of the inserts (0.6 cm2) or the diffusion area between cells in 
33 
 
Franz diffusion system (0.63585 cm2), md is the initial mass of calcein in donor chamber (g) and 
t is the time (3 hours = 10800 s). 
 
2.8 Scanning Electron Microscopy  
To investigate the surface topography of the phospholipid vesicular membranes, the 
Scanning Electron Microscopy (SEM) technique was used. SEM scans the surface with a 
focused beam of electrons. The electrons interact with atoms in the sample, producing different 
signals that contain information about the sample's surface topography and composition. SEM 
studies were performed by an Ultra-High Resolution Analytical Scanning Electron Microscope 
HR-FESEM Hitachi SU-70, designed to work though the ultralow landing voltage. The SC 
models were prepared in the usual way, the membranes were cut out from support and placed 
on a sample's holder. The 1 kV landing voltage was used for observing soft surfaces without 
covering. 
 
2.9 Phospholipid quantification assays 
The liposome preparation and calcein permeation studies were performed only with buffer 
HEPES (pH 7.4). The agitation was used during the permeation assays for two phospholipid 
vesicular membranes. 0.4 mL of an aliquot from the receiver chamber for last point (3 h) was 
dried in a Pyrex tube in the oven at 120°C. The standard curve tubes were treated in the same 
manner.  
The Pyrex tube was placed in a beaker containing 
paraffin oil. Perchloric acid (0.4 mL, 70%) were added, 
covered each tube by marbles to prevent loss of 
perchloric acid fumes (Fig. 15) and heated for 1 h at 
180°C for mineralization on the ceramic heating plate 
(IKA Magnetic Stirrers, C-MAG HS 7 Package) with 
connecting a contact thermometer (ETS-D5, IKA Hot 
Plates Accessories). 
 
 
Fig. 15 – Phospholipid quantification assays setup 
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 After cooling, the reagents were added in order: water (1 mL), 1.25% (w/v) ammonium 
molybdate (0.4 mL), and 3% (w/v) ascorbic acid solution (0.4 mL). The additions were made 
rapidly and the tube contents were mixed after each addition with a vortex. All the tubes were 
boiled at 100°C for 5 min on the ceramic heating plate. The absorbance was measured at 797 
nm in a V-660 UV-VIS Spectrophotometer (JASCO Germany Labor). To obtain standard 
calibration curve, Monopotassium phosphate (KH2PO4) solution 1 mM was used.
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2.10 Statistical Analysis 
Results are reported as a mean ± standard deviation from a minimum of three independent 
experiments. The Student’s t-test (two-tailed) was used to evaluate the statistical significance of 
any differences in mean values in experimental groups. Differences were considered significant 
at p < 0.05. Statistical analysis was computed using GraphPad Prism Software (Version 6.01 for 
Windows; GraphPad Software Inc, San Diego, CA, USA). 
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III RESULTS AND DISCUSSION 
3.1 The structure of the phospholipid vesicle-based SC model 
This work aimed to produce a SC model, which more closely mimic the human SC based on 
a specific chosen liposome composition, to further estimation of skin permeability. Thereby, the 
first step was to examine the structure of the designed and prepared phospholipid vesicle-based 
barrier. To achieve this purpose, the following techniques were employed: 
 DLS to assess the size of both types of liposomes used in the model; 
 scanning electron microscopy to visualize the surface of the phospholipid vesicular 
barriers; 
 phospholipid quantification assay to determine the stability of the barrier. 
Different size of liposomal structures was used to promote the spreading into the pores and 
onto the membrane surface.36 This hypothesis is based on previous literature data: the liposome 
extrusion makes the vesicle’s sizes conformable to the size of the filter pores.73 Also, the 
repetitive extrusion cycles through the same filter have been shown to decrease the liposome 
size.74 The skin SC model was produced by first adding smaller liposomes which pass into the 
pores, and then larger liposomes that made an expected layer on top of the membrane filter.6 
 
3.1.1 Determination of size and polydispersity of the liposomes 
The liposome suspensions were produced as multilamellar large vesicles (MLVs) with a 
main size distribution in the range of 800-1200 nm and LUVs with mean diameter 100-400 nm. 
In order to gather data about the diameters and polydispersity (PDI) of each liposome batch 
used in the present study, the DLS technique was employed. The collected results are 
summarized in Table 9. 
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Table 9 – Characterization of the liposomes populations 
Parameters MLVs LUVs  
Effective diameter (nm) 979 ± 84 251 ± 34 
Polydispersity index (PDI) 0.37 ± 0.01 0.24 ± 0.02 
Data expressed as mean ± standard deviation (n = 10). 
 
The MLVs exhibited an average size of 979 ± 84 nm, which makes them possible to apply 
on top of the inserts. The MLVs demonstrated a bimodal size distribution, that is, two clear 
vesicle populations could be detected. The mean size of the main fraction, which contained 
more than 55% of the liposomes, was approximately 535 nm, and that of the smaller fraction, 
containing less than 45% of the liposomes, was approximately 3615 nm (Fig. 16A). In 
agreement, all the MLVs prepared in this study showed relatively large polydispersity index 
(PDI) values (0.37 ± 0.01), which indicates a heterogeneous distribution of vesicles of many 
different diameters. 
 
 
Fig. 16 – Size distribution of vesicles used in this study measured by DLS. (A) MLVs; (B) LUVs 
The LUVs displayed an average size of 251 ± 34 nm. They are smaller than the MLVs, as 
expected, and suitable to fill in the membrane pores. The LUVs also showed a bimodal size 
, 
%
 
, 
%
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distribution, 103 nm (20%) and 354 nm (80%), which is shown in Fig. 16B. The PDI is 0.24 ± 
0.02, slightly higher than 0.2, indicating a more homogeneous range of liposome sizes. 
For the purpose of comparison, we determined the mean diameters of the liposomes, which 
passed through the filter during the preparation of SC model, and for that, were not incorporate 
within the phospholipid-vesicular based membrane. It was 198 ± 8 nm (n=2). 
In sum, regarding the results for particle size, LUVs demonstrated smaller average size (251 
± 34 nm) that allow them to congestion inside membrane pores (400 nm), and MLVs had bigger 
diameter (979 ± 84 nm), which doesn't allow to penetrate throughout the membrane barrier, but 
makes possible to form a tight liposome layer on top of the membrane surface. Thus, the 
phospholipid vesicular barrier preparation process followed accordingly: first, a portion of the 
liposomes pass via the membrane filter (the liposomes were found in the infiltrate by 
microscopy), but after the several steps, the pores are filled with LUVs and a layer on the top 
begins to form by MLVs. At the end, the membrane loses its initial throughput capacity, a 
supernatant is formed and finally the barrier model can be obtained. 
 
3.1.2 Scanning electron microscopy analysis 
The surface morphology of the SC models was examined by scanning electron microscopy 
(SEM). SEM analysis was performed with low-landing voltage to visualize the liposome layer 
and the micrographs are shown in Fig. 17. The images present the phospholipid vesicular 
barriers with different storage conditions: the recently prepared barrier model (A-C) with various 
magnifications and the membrane model stored for about 4 months at 4°C (D). 
SEM micrographs confirmed that the SC model have a tightly, non-porous surface, which 
completely covers the filter (Fig. 17A). On the next image (Fig. 17B) an uneven surface with 
small round-shape particles, hypothetically, liposomes vesicles and some crystals of phosphate 
buffer can be observed. Even at very high magnification, it is possible to observe that the 
liposome layer is coating the filter, the pores are not discovered, and a border of detached layer 
is also visible (Fig. 17C). Moreover, it is worth noting that this image had some similarities with 
micrograph of human SC, obtained from previous studies (Fig. 18).7 
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Fig. 17 – SEM images of (A-C) freshly prepared, and stored for 4 months at 4°C (D) the phospholipid vesicular barriers.       
The scale bar is indicated below images 
 
A large amount of pores is presented on the surface of the barrier upon 4 months stored 
(Fig. 17D). We can probably assign as the absolute absence of the liposome layer because we 
can observe the pure filter and the initial pores (diameter is 400 nm). This fact is related with the 
stability studies described below. 
 
          Fig. 18 – SEM images of untreated human skin
7
 
39 
 
3.2 Characterization of the phospholipid vesicle-based model 
3.2.1 Calcein permeability and electrical resistance 
In order to get significant data from the permeability assays, a confirmation of the SC 
models was carried out by two independent assessments: testing the penetration of hydrophilic 
fluorescent marker (calcein) and the transepithelial electrical resistance (TEER) to validate the 
integrity of the barriers. Calcein was chosen as reference compound with pKa 6.67 48, which 
presented a weak acid ionized form at working with pH 7.4 and showed good ability to diffuse 
across liposome layer in the barriers. TEER is commonly considered as a good indicator of 
barrier tightness.50 The electrical resistance was measured after each permeation experiment 
i.e. after 3h incubation in the sample solution. The control measurements were performed by 
using the pure membrane filter (Fig. 19). 
 
Fig. 19 – The permeability of calcein for the pure filter inserts (control) and freshly prepared phospholipid vesicular barriers. 
The electrical resistance is marked by the diamond dots. The values denote the mean ± S.D. (n = 3) 
 
In the case of freshly prepared SC models, values for calcein permeability and TEER, 
were significantly lower and higher, respectively, when compared to pure control inserts. The 
results confirm the barrier integrity of the prepared models. Besides the increasing in calcein 
permeability and decreasing in TEER of the control values are assumed to exclusively reflect 
leakage of the pure membrane filter.   
Nevertheless TEER- and calcein permeability-values are rather dissimilar from earlier 
published data for the SC model.6, 69 Probably this can be connected with the case that the other 
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lipid composition, the filter area is smaller, acceptor volume here are bigger than in the earlier 
reported set-up. Also, the sensitivity of the electrode is not constant, the thickness of liposome 
layer is not analogous with previous studies, which were performed in same conditions in a one 
research group. 6  
 However, in the current experimental arrangement, it could be concluded that in terms of 
calcein permeability and TEER, the integrity of the phospholipid vesicular barriers is maintained. 
 
3.2.2 Phospholipid quantification 
To verify the barrier integrity during the calcein permeation studies, the presence of 
phospholipid in the acceptor chambers after 3 h incubation in HEPES buffer was explored. The 
amount of phosphorous in the acceptor chambers was quantified by spectrophotometric 
determination. Briefly, the samples probably containing phosphate are converted to inorganic 
phosphorus by mineralization, then the phosphorus react with ammonium molybdate to produce 
PMo12O40
3−. This anion is then reduced by ascorbic acid to form the blue colored 
phosphomolybdic complex (molybdenum blue).75 Nevertheless, a blue color was not observed 
and measured absorbance at 797 nm shown values at the range 1.1 – 1.9%, which indicates 
the lack of phosphorus. 
No egg phosphatidylcholine could be detected in the acceptor phases, that confirmed the 
barrier integrity during the calcein permeation assays in terms of release of phospholipid and 
that is consistent with previous study.69 
 
3.2.3. Storage stability  
The storage stability of phospholipid vesicular barriers was estimated as a weighty argument 
in cost efficiency analysis of the drug development process. If SC models don't lose their 
permeability properties during a certain period of time, the cost minimization and an effortless 
planning can be reached by producing larger batches. 
The stability of the barriers upon keeping at two various temperatures was assessed by 
evaluating the calcein permeation after different storage times. The calcein permeability (Papp) 
values received from the developed SC models stored at the various temperatures are 
presented in Fig. 20. 
41 
 
0
25
50
75
100
125
150
0
20
40
60
80
100
120
freshly prepared 1 week, -20°C 1 week, -80°C 2 week, -20°C 2 week, -80°C
E
le
c
tr
ic
a
l 
re
s
is
ta
n
c
e
, 
Ω
 
P
a
p
p
 o
f 
c
a
lc
e
in
, 
1
0
-6
 c
m
/s
e
c
 
freshly prepared
1 week, -20°C
1 week, -80°C
fresh
** 
** 
** 
** 
Papp of c lcein, freshly prepared 
Papp of calcein, -20°C  
Papp of calcein, -80°C  
Electrical resistance 
Fig. 20 – Effect of storage conditions: -20°C and -80°C on calcein permeability and electrical resistance through the phospholipid 
vesicular barriers. Error bars represent the standard deviations (n=2 and for freshly prepared n=4). **P<0.01 in relation to freshly 
prepared membrane (control) 
 
As can be seen from the results in Fig. 20, the permeability did not significantly differ from 
those of the control (freshly prepared) for up to 2 weeks of storage at -20°C. These conditions 
show great promise without any considerable variations with respect to the permeability of 
calcein.  
On the contrary, a 25% increase in the permeability of calcein was observed after 1 and 2 
weeks of storage at -80°C. The results of the evaluation of phospholipid vesicles barrier using 
calcein are likewise as previously published stability results for PVPAs, which also designated a 
limit of 2 weeks of storage at -70°C.36, 39 This dissimilarity in the storage temperature can be 
explained based on the SC barrier more complex lipid composition, which showed more 
sensitiveness for low temperatures. 
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In summary, the SC models can be prepared in larger batches, and be saved in a freezer 
and will be ready to use after 2 h of thawing on any day during the recommended period of 
storage. 
 
3.2.4 Barrier stability under a pH range 2.0 to 8.0 
The barrier stability under different pH conditions can provide information on the applicability 
of the developed phospholipid vesicle barriers in the screening for drugs in a wide range of pKa. 
The stability of the SC models towards changes in pH in a range from 2.0 to 8.0 was examined 
by the determination of calcein permeation under various pH values in the donor chamber. The 
acceptor chamber contained PBS buffer at pH 7.4. The permeability (Papp) of calcein under 
distinct pH conditions are presented in Fig. 21. 
 
Fig. 21 – The Papp and TEER values of calcein at pH 2.0, 7.4 and 8.0. Data expressed as mean values ± SD (n=5) 
 
The developed SC models seemed to be stable due to the unaltered permeability of calcein 
over the pH range explored. It is in agreement to earlier reported experimental results of 
fluorescein permeability for PVPA membranes.6 Thereby, the prepared phospholipid vesicle 
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membranes do not forfeit their wholeness at pH margins from 2.0 to 8.0 and can be used for the 
screening of drugs with acidic and basic properties. 
 
3.3 Characterization of drug–membrane interactions 
3.3.1 Use of pH changes to influence the permeability of acidic and basic drugs 
As described above, the integrity of the SC models is persisted at the pH range from 2.0 to 
8.0 that allow the permeability studies of ionogenic drugs dependent on pH changes. Thus, the 
calcein permeability with caffeine and methotrexate (MTX), basic (104 μg mL-1) and acidic 
(100 μg mL-1) drug compounds, respectively, was tested at two different pH (2.0 and 8.0). The 
pH in the donor chamber was maintained at pH 7.4. The Papp values are given in Fig. 22.  
From the chart, the permeability of calcein in the presence of MTX decreased with 
increasing the pH, for caffeine no significant effect was observed. For MTX the reduction in 
permeability was significant from pH 2.0 to 7.4 and from pH 7.4 to 8.0. For caffeine, the 
permeation results likely depend on the low amount of uncharged molecules at both these pH 
values, as caffeine has a pKa value of 14.0. As caffeine is a basic drug and MTX an acidic drug 
(pKa 4.7) this indicates that the permeability is slightly reducing with enhancing degree of 
ionization of MTX. 
Most drugs are weak acids or weak bases, in which the relation of the charged (ionized) to 
uncharged (nonionized) form is contingent on the drug’s pKa, and the pH of the surroundings. 
At same pH and a drug’s pKa, the protonated and nonprotonated forms are in the equilibrium. If 
the pH is less than the pKa (the redundant protons are present), the protonated form of a drug 
prevails.48, 76 Therefore, weak acid (MTX) subjected to low pH environment (pH 2.0) is preferred 
to diffuse across barriers while, weak bases are not, that is confirmed by the increased 
permeability shown on Fig. 22. This process has an opposite effect at higher pH (pH 8.0).  
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Fig. 22 – The permeability (Papp) values for caffeine and methotrexate (MTX) at pH 2.0, 7.4 and 8.0 in the apical medium and 
pH 7.4 the basolateral medium (n=3). ****P<0.0001 between MTX pH2 and MXT pH8 
The discovered changes in calcein permeability with drugs reflect changes in the drug's 
ionisation state, but not of pH-dependent changes in the phospholipid vesicles barriers since the 
SC membranes are stable this pH interval. Our results also comply with the previous studies.69 
 
3.3.2 Influence of surfactants and co-solvents in the phospholipid vesicle-based 
model 
In this assay, it was examined the suitability of the SC model for permeability evaluations in 
the presence of surfactants and co-solvents. This was reached by measuring the stability of the 
phospholipid vesicular barriers in the presence of surfactant and co-solvents from point of view 
of calcein permeability and TEER.   
Some drugs are insoluble in aqueous-based solvents, therefore various co-solvents were 
used for the design and optimization drug formulation for TDD.77 DMSO and oleic acid are well 
known skin permeation enhancers 78, cremophor® is non-ionic surfactant.79 DMSO is a potent 
aprotic solvent and can be contributing for topical delivery for various drugs.78  DMSO is 
connecting with the intercellular lipid region of SC and meddling in the packing geometry, that 
promotes increment of skin permeability.80 Oleic acid is the most popular of long chain fatty 
acids, which can enhance the drug absorption via the skin.78 Oleic acid treatment contributes 
the reduced ability of skin barrier function by making a new type of lipid domain together with 
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SC lipid, that works as a skin penetration enhancer.81 Cremophor® is a frequent component, 
which is using in the low-water soluble drug development.82 
The testing of the integrity of the SC models was carried out by determining the calcein 
permeability in the presence of DMSO, oleic acid and cremophor® with concentration 10% (v/v) 
with calcein solution in the donor chamber for each compound. TEER measurements were 
performed after completed studies. The results are given in Fig. 23. 
The results in Fig. 23 show that the presence of DMSO, oleic acid and cremophor® in the 
solution in the donor chamber did not influence the permeability of calcein at the studied 
conditions, as the results are not statistically different. The electrical resistance confirmed the 
integrity of the phospholipid vesicles barriers. According to the results for cremophor®, a little 
diminution of TEER with increasing permeability of calcein was found, but statistical analysis 
confirmed that no statistical differences in relation to calcein compound alone. The data has the 
correlations with published paper.69 Thereby, the phospholipid vesicle membranes seemed to 
be reconcilable with DMSO, oleic acid and cremophor® for a concentration of 10% (v/v). They 
are not disrupting the structure of the barrier, which renders them suitable as additives in this 
model. Thus, the SC models are adequate for the development and optimization of the drug 
formulations in TDD using the listed surfactants and co-solvents compounds. 
 
Fig. 23 – The permeability (Papp) values for calcein in absence (control) and presence of different co-solvents and surfactant in 
the donor compartment. Error bars denote the standard deviations (n=3) 
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3.3.3 Influence of drug substances on the SC model 
Estimating the drug permeation via the skin is indispensable in the design of (trans)dermal 
delivery drugs. The developed SC model can be validated by evaluating the permeability of 
different drugs. 
Preliminary assays have shown that some drug compounds can influence the calcein 
permeability (see Fig. 22), here's why permeability experiments with the hydrophilic marker 
calcein together with caffeine, naproxen, diclofenac, MTX and cyclosporine respectively, were 
made to consider if the drugs interact with the barrier and how they could influence the 
permeability of a calcein. The results from the permeability experiments with calcein under the 
presence of caffeine, naproxen, diclofenac, MTX and cyclosporine are shown in Fig. 24. 
 
Fig. 24 – The permeability (Papp) values for calcein (bars) and the electrical resistance (x) across the SC model in absence 
(control) and presence of caffeine, naproxen, diclofenac, MTX and cyclosporine. Each result represents the mean ± standard 
deviation for n=3 measurements. ****P<0.0001 in relation to calcein alone (control) 
 
It was found that all drugs had an influence on the calcein permeability. The permeability of 
calcein increased to a large extent when caffeine was present and decreased when other drugs 
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were present in the donor compartment. These changes possibly related to the chemical 
properties and structure of the drugs. 
Caffeine is a small hydrophilic molecule, which increased the calcein permeability via 
phospholipid vesicles membrane because it has low affinity with the lipid layer and low 
molecular weight (Mw = 194 g mol-1), that did not block its passage. Also, TEER measurements 
showed that electrical resistance decreased slightly, with no statistical meaning. 
On the contrary, MTX is a lipophilic drug with medium interactions with lipids and 
Mw = 454 g mol-1, which longer stays on the liposome layers, that corresponds to lower 
permeability values compare to calcein alone. 
For cyclosporine, there was observed a considerable diminution in permeability of calcein, 
that can be linked with the highest molecular weight (Mw = 1203 g mol-1) from the selected 
drugs and hydrophobic character. Cyclosporine has high affinity with the lipid surface and the 
big size molecules can block free transition of calcein solution throughout the SC membrane 
filter. 
A reduction in the permeability of calcein was also noticed for naproxen and diclofenac, but 
not to the same extent as for cyclosporine. The obtained values are very similar and possibly 
establish linkage between naproxen and diclofenac resemblances, such as molecular weight 
(230 and 318 g mol-1, respectively), PSA, pKa, chemical structure and hydrophilic nature (Table 
8). 
Consequently, the developed SC model can be used to evaluate the nature of drugs and 
predict the permeability properties in early stages of drug development. 
 
4 Comparison the SC model with pork skin model 
The capability of an in vitro model to find little variations in the penetration of drug carriers or 
formulations and to give reproducible permeability results are of utmost importance. To 
demonstrate the usefulness of the phospholipid vesicles membranes in drug development and 
formulation optimization, a number of experiments using Franz diffusion cells and porcine skin 
as a barrier model were performed. 
The studied conditions were identical to the previous experiments with the developed SC 
models in following parameters: same tested solutions, buffer, temperature and lack of agitation. 
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It is useful to note, one of the differences is using a full epidermis part of pork skin, not only SC 
layers, that's why we can observe some dissimilarities in the order of magnitude of Papp values.  
 
4.1 Effect of storage conditions 
The storage stability is one of most important factor in planning during drug development. 
The calcein permeability results for the SC model and porcine skin stored at 4°C and -20°C are 
presented in Fig. 25.  
 
Fig. 25 – Correlation between the calcein permeability (Papp) values from SC models (n=2) and the obtained values from pork 
skin assay (n=3) in terms of storage stability. Error bars represent standard deviations 
 
The results from the stability experiments with the pig ear skin using the Franz diffusion cells 
showed that the permeability of calcein was not significantly different from that of the control 
(freshly prepared) up to 2 days of storage at 4°C. However, a small reduction in the permeability 
of calcein was observed after 1-week of storage at -20°C. Low temperatures can effect on the 
permeability of pork skin (probably, by collapsing the pores) and on the enzyme system involved 
in metabolic process.83 According to the described results, the storage of porcine skin is not 
recommendable at -20ºC. 
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At the same time, the phospholipid vesicles barriers can be stored up to 2 weeks at -20°C 
without any significant changes in the calcein permeability (Fig. 25), that is an important 
advantage in comparison with to the commonly used animal skin model. 
 
4.2 Effect of various pH values (2.0 – 8.0)  
The permeability studies at the pH range 2 to 8 were performed as described earlier 
(Section 2.6). In short, the calcein solutions with different pH (2.0, 7.4 and 8.0) were placed in 
the donor chambers. The acceptor chambers were prefilled with phosphate buffer (pH 7.4). The 
obtained results are shown in Fig. 26. 
 
Fig. 26 – Correlation between the calcein permeability (Papp) values from SC models (triangles, n=3) and from pig ear skin 
model (bars, n=4) towards pH range from 2.0 to 8.0. *P<0.05 in relation to calcein permeability at pH 7.4 for pig ear skin model 
 
The results on Fig. 26 show that the porcine skin was able to maintain the calcein 
permeability at the pH values 7.4 and 8.0. However, a significant statistical decrease (P < 0.05) 
in the calcein permeability was evident at pH 2.0. These data indicated that low pH values had 
an influence on the permeability of the pork skin, and the future evaluations at this pH can be 
give an erroneous result. While the developed SC model had correlations with used pig skin at 
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the pH range 2.0 to 8.0 that confirmed its ability for the permeation evaluation of a wide range of 
drugs. 
 
4.3 The influence of co-solvents and surfactant 
In the present study, DMSO, oleic acid and cremophor® were applied as additives to calcein 
solutions for the evaluation their influence on permeability of tested SC model and porcine skin 
model. Fig. 27 shows the permeability matching between the phospholipid vesicles barrier and 
pig ear skin model. 
 
Fig. 27 – The calcein permeability (Papp) values from SC models (triangles) in comparison with Papp for pork skin from Franz 
diffusion cell assays (columns) in presence of the co-solvents (n=3). **P<0.01 in relation to control (calcein alone) 
 
According to the information detailed in the Fig. 27, the pork skin doesn’t maintain the initial 
calcein permeation with the addition of 10% (v/v) DMSO, but oleic acid and cremophor® don't 
affect the Papp of calcein. Therefore, for testing and optimization of drugs in the porcine model 
DMSO should be avoided as co-solvent. 
The benefits of the developed SC model include the stability in the presence of the studied 
co-solvents and surfactant, which gives more opportunities in optimizing drug formulations. 
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4.4 Effect of acidic and basic drugs 
To compare the effects of acid and basic drugs on the calcein permeability for the SC model 
and the pork ear model, at the pH range (2.0 - 8.0), the analogous calcein solutions containing 
caffeine and MTX additives were chosen. The results are presented in Fig. 28. 
 
Fig. 28 – Correlation between the calcein permeability (Papp) from pig ear skin experiments (left side, n=3) and from SC models 
(right side, n=3) in the presence of the acidic (MTX) and basic (caffeine) compounds toward the pH range from 2.0 to 8.0. 
*P<0.05 in relation to caffeine pH 8 for pig skin model and ****P<0.0001 between MTX pH2 and MXT pH8 for SC model 
 
The calcein permeability in the presence of MTX for pork skin (Fig. 28, left side) didn´t show 
meaningful changes at the chosen pH interval. The relation between pKa and Papp do not occur, 
which can be explained by the influence of low pH on the porcine skin, which decreased the 
permeability (Fig. 26). The SC model is not liable to pH changes, and the correlation between 
pKa and Papp are shown on Fig. 28 (right side), where significant differences (*P<0.0001) in Papp 
calcein with MTX can be observed. The permeability of the calcein with caffeine as addition at 
lower pH (2.0) demonstrated a considerable diminution (P<0.05) of Papp in relation the solution 
with higher pH (8.0). In fact, it is confirmed that the reduction in calcein permeability could be 
generated by lower pH value. We cannot make the conclusions about the influence of basic 
drug on calcein permeability towards pH range because of the described reasons. 
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4.5 The influence of drug substances  
The permeabilities studies were performed with Franz diffusion systems and pork skin as a 
model barrier. The technique and conditions were an analogous to permeability assays with the 
phospholipid vesicles membranes. The control was a calcein solution without additives. The 
matching effects are indicated on Fig. 29. 
All tested drugs had an influence on calcein permeability via pork skin, that were confirmed 
by substantial changes in the relation to pure calcein solution, which are designated on Fig. 29. 
The drugs were ranked based on their permeability values for the pork skin and SC models in 
decreasing order as follows: caffeine, naproxen, diclofenac, MTX and cyclosporine, that 
corresponded with their molecular weight. 
 
 
Fig. 29 – The permeability (Papp) values for calcein for pork skin (bars) and the SC model (triangles) in absence (control) and 
presence of caffeine, naproxen, diclofenac, MTX and cyclosporine. Each result represents the mean ± standard deviation for 
n=3 measurements. *P<0.05, ** P<0.01, **** P<0.0001 in relation to calcein (alone) for pork skin. 
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Thus, the highest Mw (cyclosporine) exhibited the lowest Papp value, and a correlation was 
observed for both the SC and the pig ear models. The cyclosporine is a big and very lipophilic 
molecule, which has strong affinity with lipid even at low concentrations (36 μg mL-1).  
The MTX is also lipophilic compound with molecular weight (454 g mol-1) lower than 
cyclosporine molecule. The calcein permeability with MTX is lower than alone calcein because 
of the interaction with the lipid layers, and higher than calcein permeability in presence of 
cyclosporine owing to smaller size. These evidences were noted for either the SC model and 
the pork skin equally. 
Diclofenac and naproxen have similar chemical properties, pKa, PSA and lipophobic 
character here's why same permeability values were viewed in the Franz diffusion cell studies 
and with little shift in the prepared phospholipid vesicles barriers. These deviations can be 
accounted for the size of molecules, probably, block aqueous pores in the SC membranes that 
slightly reduce the calcein permeability. 
Caffeine is a small drug with very hydrophilic properties, which showed higher calcein 
permeability compared with other drugs. The differences between the pork skin and the 
developed SC model can be explained based on the full-thickness of the skin epidermis that 
protects rapid penetration via skin for the caffeine molecules, in contrast with the phospholipid 
vesicles model, which mimicking only the SC layer. 
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IV CONCLUSIONS AND FUTURE PERSPECTIVES 
With the results showed along this thesis, it is feasible to perform some final observations 
concerning the principal conclusions of these studies. 
According with the first task, the goal was to design and characterize a human SC model. It 
is possible to claim that the chosen lipid composition allows to produce the phospholipid 
vesicles barriers, which mimic human SC. SEM images confirmed their structure, which 
presents similarity with human SC. Moreover, these barriers remain stable through 2 weeks at -
20°C and show the stability towards pH range from 2.0 to 8.0 and to the presence of co-solvents 
and surfactant. Also, the developed in vitro model was able to detect permeability differences 
when the drugs were present in the calcein solutions and demonstrated a good correlation with 
chemical properties of selected drugs, especially with the molecular weight and an acidic/basic 
character. 
Regarding the second purpose, the aim was to validate the developed model with the most 
commonly used animal skin model. Based on the data obtained from Franz diffusion cell 
experiments, it was possible to detect the relationship in the calcein permeability between the 
phospholipid vesicles membranes and porcine ear skin, that was clearly visible in the 
permeation studies with the additives of drugs. Besides, prepared SC models showed some 
advantages: better storage stability and an independence from pH and co-solvents. 
Hence, the phospholipid vesicles barriers were found to be superior to pork skin by the 
described parameters and according to their ease of use, cost effectiveness and ability to 
replacement animal skin for permeability tests of potential drug formulations early in the 
development process. 
Future experiments, which include wide range of drugs/chemicals and formulations without 
calcein solutions, need to be performed to prove the developed SC models’ full capacity as a 
model for human SC.  
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